Track market-moving stories before they get noisy

Key Takeaways RGTI made its 108-qubit Cepheus-1-108Q system broadly available across major quantum platforms.RGTI's Q1 revenue nearly tripled to $4.4 million, driven by Novera QPU deliveries and contracts.Rigetti targets quantum advantage with a ~1,000-qubit system, 99.9% gate fidelity and error mitigation. Rigetti Computing (RGTI - Free Report) is strengthening its position in the quantum computing race through a combination of technological advancements and expanding customer adoption. During the first quarter of 2026, the company made its 108-qubit Cepheus-1-108Q system generally available through Rigetti Quantum Cloud Services, Amazon Braket, Microsoft Azure Quantum and qBraid. Management believes the platform is among the world’s most powerful gate-based quantum computers and the largest modular quantum computing system currently on the market.

Built using 12 interconnected 9-qubit chiplets, the system validates Rigetti’s chiplet-based scaling architecture, a key element of its long-term roadmap toward larger and more capable quantum systems. The company also highlighted continued progress in improving gate fidelity and performance, with management targeting approximately 99.5% median two-qubit gate fidelity later in 2026 while maintaining its speed advantages.

Beyond technology milestones, Rigetti continues to gain customer traction across both cloud and on-premises deployments. First-quarter revenues nearly tripled year over year to $4.4 million, primarily driven by deliveries of Novera quantum processing units (QPUs) and related contracts. The company continues to expand its installed base through sales to universities, research institutions and national laboratories. It is also reporting growing interest from commercial customers in industries such as materials science, logistics and financial services.

Importantly, management reiterated its belief that Rigetti can achieve quantum advantage within roughly three years, targeting a system with around 1,000 qubits, 99.9% two-qubit gate fidelity and integrated error mitigation capabilities. Backed by approximately $569 million in cash and no debt, Rigetti is well positioned to continue investing aggressively in scaling its technology platform and capitalizing on emerging opportunities in the rapidly evolving quantum computing market.

Peers UpdatesIonQ (IONQ - Free Report) recently opened a new 22,000-square-foot quantum computing R&D laboratory and semiconductor chip testing facility in Boulder, CO, to support the development of future generations of its trapped-ion quantum computing systems. The facility will enable the company to design, test and refine advanced semiconductor ion-trap chips, with plans to install its first quantum computer later this year. By expanding its presence in Colorado's growing quantum technology ecosystem and leveraging the region's deep-tech talent pool, IONQ aims to accelerate innovation, scale production capabilities and advance its roadmap toward fault-tolerant quantum computing.

D-Wave Quantum (QBTS - Free Report) recently announced that it has entered into a non-binding Letter of Intent with the U.S. Department of Commerce for proposed funding of up to $100 million under the CHIPS and Science Act. The initiative aims to support the advancement and large-scale deployment of the company’s annealing and gate-model quantum computing technologies. As part of the proposed arrangement, the U.S. government would receive a $100 million equity stake in D-Wave.

The funding is expected to help expand quantum system development at D-Wave’s planned facility in Boca Raton, FL, as well as its existing research and development operations. The investment could accelerate the commercialization of next-generation quantum platforms, including a 100,000-qubit annealing system and a 10,000-qubit gate-model computer. It could also enhance D-Wave’s competitive standing in the rapidly evolving quantum computing market and support U.S. leadership in critical advanced technologies.

Rigetti Computing’s Price Performance, Valuation and EstimatesShares of RGTI have lost 1.8% in the year-to-date period compared with the industry’s decline of 11%.

Image Source: Zacks Investment Research

From a valuation standpoint, Rigetti trades at a price-to-book ratio of 12.39, above the industry average. RGTI carries a Value Score of F.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Rigetti’s 2026 earnings implies a significant 70.3% improvement from the year-ago period.

The company currently has a Zacks Rank #4 (Sell).

Image Source: Zacks Investment Research

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. 

Rigetti Computing (NASDAQ:RGTI) stock is 1.4% higher to trade at $19.97 today. The quantum computing concern is down 9.7% in 2026 and 21% in June alone, as high beta growth stocks have suffered from tech sector profit taking. The upside though, if past is precedent, is that RGTI has pulled back to a historically bullish trendline. 

According to Schaeffer's Senior Quantitative Analyst Rocky White, Rigetti stock is trading within 0.75 times of the 50-day moving average's 20-day average true range (ATR), after spending at least 80% of the previous two weeks and 80% of the prior 42 trading sessions above that trendline. This setup has appeared five times during the last decade. One month later, the stock was higher 60% of the time after these signals, averaging a 22.7% gain.

A move of similar magnitude would have RGTI filling its June drawdown, and testing the downtrend line from those October highs above $58, seen below. It's also worth noting Rigetti's 14-Day Relative Strength Index (RSI) is below 50, an area that preceded a frenetic rally in late May.

A short squeeze could help as well. Short interest is down 2% in the most recent reporting periods, yet the 49.21 million shares sold short account for 15% of the shares' total available float.

Key Takeaways D-Wave Quantum is among nine firms in DoC letters of intent tied to $2.013B in proposed incentives.QBTS jumped 17.1% in 10 days as investors cheered funding for U.S. quantum expansion.Honeywell's Quantinuum may receive up to $100M to advance trapped-ion quantum computing. Over the past 10 days, the most prominent quantum-computing ETFs, Defiance Quantum ETF (QTUM - Free Report) and WisdomTree Quantum Computing Fund (WQTM - Free Report) , have gained around 7-8%. The rally followed the U.S. Department of Commerce's (DoC) announcement of letters of intent with nine quantum-related companies for approximately $2.01 billion in proposed CHIPS and Science Act incentives.

Image Source: Zacks Investment Research

This proposed funding package represents one of the most significant federal investments in quantum computing to date, reflecting Washington's growing efforts to maintain U.S. leadership in this space. The government currently views this as a strategically important initiative for national security, technological resilience and future industrial competitiveness.

Image Source: Zacks Investment Research

Following this, investor enthusiasm for pure-play quantum stocks surged as market participants reassessed the sector's growth prospects and funding outlook. The proposed federal support has boosted confidence in the industry's long-term potential, driving sharp gains across several quantum names, with D-Wave Quantum (QBTS - Free Report) and Honeywell’s (HON - Free Report) Quantinuum emerging as key beneficiaries of the initiative.

Government Support Accelerates Quantum CommercializationQuantum computing has steadily moved up the U.S. strategic agenda since the passage of the National Quantum Initiative Act in 2018, which established a coordinated federal framework for advancing quantum research and development. The latest funding push builds on those efforts and signals a growing emphasis on accelerating commercialization and domestic manufacturing capabilities.

Reflecting the sector's growing momentum, IBM (IBM - Free Report) subsequently announced plans on May 28 to invest more than $10 billion in quantum computing through 2029. Notably, IBM is also slated to receive up to $1 billion under the proposed quantum funding program for its quantum foundry project.

2 Pureplays in Focus                     Stock Comparison Since Doc’s Announcement: QBTS, HON

Image Source: Zacks Investment Research

D-Wave: It is one of the nine names in the letters of intent and appears well-positioned to benefit from the DoC initiative. According to the company, the investment would support the expansion of its quantum computing technologies and help accelerate the development of U.S.-based quantum infrastructure. Given D-Wave's relatively modest operating scale, the proposed funding could meaningfully strengthen its balance sheet, support R&D efforts and enhance its ability to commercialize both annealing and gate-model quantum computing systems.

Following the announcement, shares of QBTS have risen 17.1% over the past 10 days. This Zacks Rank #3 (Hold) stock is expected to report earnings growth of 73.9% in 2026.

Sales and EPS Growth Rates (Y/Y %)
Image Source: Zacks Investment Research

Quantinuum (Honeywell): Quantinuum, majority-owned by Honeywell, is also expected to receive up to $100 million under the proposed program. The company said the funding would support the development of its trapped-ion quantum-computing platform and strengthen domestic quantum capabilities. As one of the industry's most advanced quantum-computing companies, Quantinuum is already generating commercial revenues and expanding enterprise adoption. The additional federal backing could help accelerate product development, scale manufacturing capabilities and further solidify its leadership position in the emerging quantum-computing market.

Honeywell has gained 6.3% during this period. This Zacks Rank #3 stock is expected to report earnings growth of 7.7% in 2026. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Sales and EPS Growth Rates (Y/Y %)
Image Source: Zacks Investment Research

The Department of Commerce recently announced letters of intent to invest $2 billion across nine quantum computing companies under the CHIPS and Science Act. In exchange, the government will receive a minority equity stake in each business.

With the U.S. government becoming a shareholder in the quantum industry, smart investors should start paying serious attention to how this technology could become the next frontier in artificial intelligence (AI).

Image source: Getty Images.

Why is the government investing in quantum computing stocks? The Commerce Department's rationale behind backing these quantum computing companies was straightforward: These investments will be used to build a domestic manufacturing base for quantum chips and accelerate the research and development (R&D) needed to produce practical quantum computers at scale.

Two recipients in particular are being funded to lead the manufacturing infrastructure. International Business Machines (IBM +0.91%) will receive $1 billion and establish a new quantum foundry subsidiary called Anderon. Meanwhile, GlobalFoundries (GFS +7.91%) is raising $375 million to build a complementary foundry capable of serving broader quantum architectures, including superconducting, trapped-ion, and photonics.

The remaining companies -- Atom Computing, Diraq, D-Wave Quantum (QBTS +2.58%), Infleqtion, PsiQuantum, Quantinuum, and Rigetti Computing (RGTI +6.51%) -- each received up to $100 million in funding to help address specific engineering variables and modalities.

Today's Change

(

6.51

%) $

1.26

Current Price

$

20.71

Among the government's quantum investments, which ones can retail investors buy? Both IBM and GlobalFoundries are publicly traded. However, their primary stories revolve around enterprise technology and semiconductor manufacturing. In reality, quantum computing is a small, niche piece of each company's AI roadmap today.

IBM's exposure to quantum computing is being outsourced to Anderon, a separate subsidiary. This means buying IBM stock does not provide investors with direct access to upside from commercialized quantum AI. The subsidiary structure effectively insulates IBM from operating losses that come with developing quantum systems.

Among the pure-play quantum companies, the public names are D-Wave, Rigetti, and Infleqtion. The remaining four -- Atom Computing, Diraq, PsiQuantum, and Quantinuum -- are currently private.

That said, Quantinuum is not completely out of reach. The company recently filed an S-1 with the Securities and Exchange Commission (SEC), suggesting an IPO could be on the horizon sooner rather than later.

Moreover, investors have several options to gain passive exposure to Quantinuum. The company is majority-owned by Honeywell (HON +6.43%); meanwhile, Nvidia (NVDA +2.30%) participated in Quantinuum's $600 million funding round back in September. Buying shares of Honeywell or Nvidia quietly puts a portion of your portfolio in the quantum opportunity.

Are quantum computing stocks good buys right now? In my eyes, the honest answer about whether quantum computing stocks are good buys is that they can be, but investors need to be selective and measure appropriate risk tolerance.

Each of the pure-play public names jumped sharply on the funding announcement. This means that some good news is already priced in. The funding from the CHIPS Act should help reduce near-term capital risk and extend development runways. However, D-Wave, Rigetti, and Infleqtion are still early-stage businesses operating in a capital-intensive sector where commercial timelines are measured in years.

RGTI data by YCharts

For investors with a long-term horizon and who are comfortable with volatility, any pullbacks that follow announcement spikes are better entry points than chasing momentum right now. For those who prefer a lower-risk angle, Honeywell, Nvidia, and IBM still offer diversified, compelling ways to ride the quantum computing wave without getting overextended.

-

Employee-driven recognition highlights the strength of D-Wave’s culture of collaboration, innovation and purpose as the company advances the commercialization of quantum computing

PALO ALTO, Calif.--(BUSINESS WIRE)--D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave” or the “Company”), the only dual-platform quantum computing company providing both annealing and gate-model systems, software and services, today announced that it has been awarded the Great Place To Work Certification™ for 2026. The recognition is based entirely on employee feedback and reflects the strength of D-Wave’s culture during a period of rapid growth and innovation, as the Company continues to expand the team advancing the commercialization of quantum computing.

Great Place To Work is regarded as a global authority on workplace culture, employee experience and leadership behaviors proven to help organizations build high-performing workplaces. The certification is awarded based entirely on employee survey results evaluating trust, respect, credibility, fairness, pride and camaraderie within the workplace.

This recognition comes at a time of continued momentum for D-Wave, as the Company scales its global workforce and intensifies its work with enterprises, research institutions and government organizations seeking to apply quantum computing to complex business and scientific challenges.

“At D-Wave, our culture is built by extraordinary people who are solving hard problems, building breakthrough technologies and helping create the market for quantum computing,” said Dr. Alan Baratz, CEO of D-Wave. “This certification is especially meaningful because it reflects the voices and experiences of our employees. As we continue to grow rapidly, maintaining the culture that enables our people to do their best work is both a priority and a remarkable achievement.”

A Great Place To Work Certification is recognized worldwide by employees and employers alike and is considered the global benchmark for identifying and recognizing outstanding employee experience.

To explore careers at D-Wave, visit: https://www.dwavequantum.com/careers/

About Great Place To Work®

As the global authority on workplace culture, Great Place To Work brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Its proprietary platform and For All™ Model help companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified™ or receiving recognition on a coveted Best Workplaces™ List.

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. It is the world’s first commercial supplier of quantum computers, and the first and only to offer dual-platform quantum computing products and services, spanning both annealing and gate-model quantum computing technologies. D-Wave’s mission is to help customers realize the value of quantum today through enterprise-grade systems available on-premises and via its Leap™ quantum cloud service, which offers 99.9% availability and uptime. More than 100 organizations across commercial, government and research sectors trust D-Wave to address complex computational challenges using quantum computing. Learn more about realizing the value of quantum computing today and how D-Wave is shaping the quantum-driven industrial and societal advancements of tomorrow: www.dwavequantum.com.

More News From D-Wave Quantum Inc.

Back to Newsroom

Key Takeaways D-Wave targets 100 logical qubits by 2032, capable of performing more than 1 million operations.QBTS plans systems in 2026, 2027 and 2028 with progressively larger error reduction factors.D-Wave says dual-rail qubits can detect about 90% of errors and achieved 99.9% two-qubit fidelities. D-Wave Quantum (QBTS - Free Report) or D-Wave is advancing its push toward commercial, fault-tolerant quantum computing. The company recently laid out a new gate-model roadmap, targeting 100 logical qubits capable of successfully performing over 1 million operations by 2032. The strategy builds on D-Wave’s expertise in high-coherence dual-rail qubits and quantum error correction, while leveraging its expertise in scaling and commercializing superconducting quantum systems.

At its first Investor Day on June 1, the company detailed a series of technical milestones underpinning this roadmap, including a 17-physical-qubit system in 2026 that supports logical error rates two times lower than physical error rates. D-Wave also expects to complete a 49-physical-qubit system in 2027, capable of a 20-fold error reduction factor and a 181-physical-qubit system in 2028 that can deliver a 2,000-fold error reduction factor.

Unlike many industry peers that focus on scaling physical qubits, D-Wave is pursuing an approach centered on reducing errors at the hardware level. Its dual-rail qubit architecture incorporates error detection directly into the qubits, allowing errors to be detected during computation at the single-qubit level. 

According to D-Wave, its dual-rail qubits can identify approximately 90% of errors as they occur, helping reduce the number of physical qubits required to perform error correction. This is in contrast to many other gate-model hardware modalities that cannot detect qubit errors. The company has also demonstrated 99.9% two-qubit fidelities with error detection, meaning physical errors occur only about one in every 1,000 operations.

Also, the roadmap calls for achieving a Lambda of 10, which D-Wave expects will reduce errors by a factor of 10 for each increment in error correction, making it possible to achieve fault-tolerant quantum computing with significantly fewer physical qubits.

What QBTS’ Peers Are Up To?IonQ (IONQ - Free Report) , last month, marked the commercial launch of Interferometric Synthetic Aperture Radar (InSAR) capabilities through its space missions line. The offering enables millimeter-precision ground deformation monitoring with fully automated tasking and data delivery, allowing customers to detect and track physical change on the Earth’s surface consistently, at a frequency and scale never previously available from a commercial SAR provider. IonQ’s InSAR solution removes manual coordination and long revisit intervals.

IBM (IBM - Free Report) has announced plans to invest more than $10 billion in quantum computing over the next five years, spanning research and development, capital expenditure, manufacturing scaling, ecosystem partnerships and M&A. Collectively, these areas are designed to speed up IBM's quantum roadmap beyond its goal of delivering the first large-scale, fault-tolerant quantum computer in 2029 and bolster U.S. quantum leadership.

QBTS Price Performance, Valuation & EstimatesOver the past three months, D-Wave shares have rallied 47.4%, well ahead of the industry’s 3.6% growth.  

Image Source: Zacks Investment Research

In terms of valuation, D-Wave is trading at a forward two-year Price/Sales (P/S) of 164.19X, significantly above its median and industry average.

Image Source: Zacks Investment Research

Estimates for D-Wave’s full-year 2026 and 2027 earnings are showing a mixed trend over the past 90 days.

Image Source: Zacks Investment Research

D-Wave currently carries a Zacks Rank #3 (Hold).  

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

IonQ (IONQ +2.67%) is battling D-Wave (QBTS +2.58%) and Rigetti (RGTI +6.51%) in one of the strangest quantum stock setups on the market. The stocks look damaged, but the businesses tell a more complicated story, with revenue growth, government contracts, acquisition potential, and major technology risk all colliding at once.

Rick Orford has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends IonQ. The Motley Fool has a disclosure policy. Rick Orford is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link, they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.

© Funtap / Shutterstock.com

Quantinuum, the Honeywell-backed trapped-ion quantum computing company, began trading on the NASDAQ today after pricing its IPO at $60 per share and raising $1.68 billion. On CNBC’s Squawk Box this morning, CEO Rajeeb Hazra delivered the line that will define the debut: “It is not 10 to 15 years out. It’s very much now. And we will only see acceleration going forward.”

That is a bold framing on a day when investors are also digesting the company’s early-stage financials. It is also a direct challenge to the long-running skeptic view that quantum is still a science project.

The Debut Quantinuum was spun out of Honeywell, which remains a majority shareholder post-IPO. The company builds trapped-ion quantum computers, including hardware called Helios. Trapped-ion systems use charged atoms held in electromagnetic fields as qubits, an approach valued for high gate fidelity and accuracy. It is the same broad architecture used by IonQ (NYSE:IONQ | IONQ Price Prediction), making IonQ the closest public comparable for investors trying to triangulate Quantinuum’s positioning.

The “Very Much Now” Thesis Hazra’s pitch leans on customers rather than theory. “We have customers today that are using our commercially available hardware and software, our full stack, to get started with their quantum journey on transforming, whether it’s their product set is pharma, their product set is financial instruments, their product set is new chemicals,” he said. He also tied quantum directly to the AI buildout: “We are in a transformative moment for the computing industry as AI and workloads take over and drive increasing amounts of value.”

He acknowledged the stage of the market, calling it “early days of a massive industry,” where the KPIs are hardware performance and accuracy.

The Profitability Question Here is where investors will scrutinize the story. Quantinuum reported 2025 revenue of $31 million and 2025 bookings of $79 million, but Q1 2026 revenue was only $1.3 million. The gap between booked commitments and recognized revenue is the central tension. Lumpy revenue is typical for pre-mass-commercialization deep tech, and the public comps show the same pattern in different forms. IonQ posted Q1 FY26 revenue of $64.67M, up 755% YoY, while D-Wave Quantum (NYSE:QBTS) reported Q1 FY26 revenue of $2.86M, down 81% YoY against a tough prior-year system-sale comp.

Government Validation and the Quantum IPO Wave Hazra confirmed Quantinuum has signed a Department of Commerce LOI: “This R&D grant is intended to allow us to be able to scale those technologies, including supply chain onshore in the US.” That ties into a broader theme. The Commerce Department’s $2 billion quantum initiative, announced May 21, 2026, included $100 million planned for D-Wave, $100 million for Quantinuum, and up to $100 million for Rigetti. Washington is treating quantum as strategic infrastructure.

For investors who want exposure today, the public comps are the established route. IonQ trades at roughly a $26.65 billion market cap with a P/E of 183 and an analyst consensus target of $67.64 ( 11 Buy, 2 Hold, 0 Sell). Polymarket assigns a 53.5% probability that the US federal government takes a stake in IonQ by year-end.

D-Wave runs both annealing and gate-model systems and is up 31.69% over the past month. Rigetti Computing (NASDAQ:RGTI) pursues superconducting chiplet architecture and has gained 100.12% over the past year. These are different architectures with different risk profiles, not equivalents to Quantinuum. For deeper background on how the architectures compare, see our coverage of the D-Wave vs. IonQ matchup.

The Takeaway Quantinuum’s listing is a real milestone. A well-funded, Honeywell-backed, government-validated trapped-ion company is now public, and its CEO insists the commercial era has started. The number to watch is the conversion of bookings into recognized revenue. CEO Hazra is asking investors to believe in acceleration. The financials say it is still early days. Quantum is moving from lab to market, and investors should size positions with that distinction in mind.

Last month, the U.S. government announced it would take stakes in a handful of quantum computing companies, including D-Wave Quantum (QBTS +2.58%) and Rigetti Computing (RGTI +6.51%). Both will receive up to $100 million in equity investment.

It has historically been rare for the U.S. government to take equity stakes in companies, with it generally happening during periods of severe economic distress. The government would also generally divest its stake once the companies were healthy.

However, the Trump administration has been more proactive with investments, instead looking to form partnerships in the interest of national security and to reduce reliance on foreign competitors. An earlier investment in Intel proved to be very fortuitous, as the stock has since skyrocketed. Meanwhile, with quantum computing expected to be the next big technology after artificial intelligence (AI), it appears the U.S. government wants to have some control over what could become a world-altering technology.

The question, though, is whether the government's investment is a validation of quantum computing technology or just a speculative bet. Are Rigetti and D-Wave worth investing in? Let's take a closer look at the two stocks.

Image source: Getty Images.

Rigetti is set to get up to $100 million over three years to help support research and development to overcome some of the big technical challenges associated with advancing and scaling superconducting quantum computing. The company's superconducting technique has proven to be very fast, but it greatly trails in accuracy to other techniques like trapped-ion.

Today's Change

(

6.51

%) $

1.26

Current Price

$

20.71

That's the biggest issue facing the company and its technology at this time. It had to delay its new 108-qubit Cepheus-1-108Q system to improve its accuracy, and when it did release it, its 99.1% 2-qubit gate fidelity (accuracy) missed the 99.5% median 2-qubit gate fidelity it was shooting for at release. The company's technology also wasn't chosen to advance to Stage B of the Quantum Benchmarking Initiative (QBI) for the U.S. Defense Advanced Research Projects Agency (DARPA). This is a Pentagon-funded program to help find and support the best quantum computing technologies, so this was a big blow.

D-Wave Quantum D-Wave Quantum will get a $100 million investment to help accelerate the development of its annealing and gate-model quantum computing technologies, specifically its 100,000-qubit annealing system and a 10,000-qubit gate-model system.

Today's Change

(

2.58

%) $

0.60

Current Price

$

23.85

D-Wave is a leader in quantum annealing technology, which is a narrower, specialized technology that shines at solving optimization problems by settling on the best or close to the best answers for complex problems. The technology is further along than broad-based quantum computing, with the company already selling machines for commercial use to industries like finance, logistics, and defense.

However, annealing is not the big quantum computing riddle companies are trying to solve, and as such, D-Wave is looking to apply its annealing expertise to traditional gate-based quantum computers. With its acquisition of Quantum Circuits, it is now pursuing a dual-rail qubit architecture, which it says will have the fidelity of the trapped-ion technology with the speed of superconducting qubits. However, it has not released any technical milestones yet that support this claim.

The verdict One notable thing about the investments the government made is that they are spread among companies pursuing quantum computing in very distinct ways. Rigetti, for instance, is taking a traditional superconducting approach, while D-Wave is pursuing a dual-rail qubit architecture based on its leadership in quantum annealing. Meanwhile, the government is also investing in Infleqtion (INFQ +4.42%), which uses a neutral-atom approach to quantum computing, and Quantinuum (QNT +9.90%), which is pursuing trapped-ion technology.

Overall, the government's investments look like a widespread bet on different competing quantum technologies and not really on individual stocks. As such, I wouldn't necessarily look at it as a validation of the stocks. I'd continue to view both D-Wave and Rigetti as highly speculative at this point, and actually prefer stocks pursuing trapped-ion technology, like IonQ (IONQ +2.67%) and Quantinuum, given the technology's accuracy edge. IonQ has achieved 99.99% 2-qubit gate fidelity, and Quantinuum 99.92%, giving them a distinct advantage in this area.

There was a time when the quantum computing investment thesis was more hype than anything. That was enough to tempt some retail investors for a while. However, markets eventually graduated to the “show me” stage. That put a burden on listed quantum computing companies to deliver tangible results.

Signs of progress are emerging, including the U.S. government recently announcing it will dole out $2 billion to nine companies in this industry. That confirms the U.S. views quantum computing as a critical industry in which it wants to lead — and that it’s willing to finance that objective.

The WisdomTree Artificial Intelligence and Innovation Fund (WQTM), which debuted last October, benefited from that announcement. The ETF is higher by nearly 13% over the past month. Some of its holdings, including International Business Machines (IBM), are among the companies enjoy Uncle Sam’s quantum spoils. While that’s a credible catalyst, it’s not the only reason WQTM merits consideration by tactical technology investors.

When Purity Matters, Consider WQTM Considering the relative youth of the quantum computing investment thesis, advisors and investors have a decent number of ETFs, including WQTM, from which to choose. However, the WisdomTree ETF stands out because of its emphasis on quantum computing purity.

Many of its holdings can be considered pure-play quantum stocks, or close to it. Some of the other ETFs in the category, meanwhile, allocate heavily to larger tech companies, with small exposure to quantum computing.

Take, for example, the pure quantum name IonQ (IONQ), WQTM’s third-largest holding. That company is about two months removed from a marquee milestone, it announced on World Quantum Day.

“By linking two commercial trapped-ion systems via quantum entanglement, IonQ demonstrated that its platform can participate in distributed, modular quantum computing, the design pattern that most serious roadmaps require at scale,” noted WisdomTree’s Christopher Gannatti. “The quantum memory technology enabling that link, fabricated from synthetic diamond, came through IonQ’s 2024 acquisition of Lightsynq.”

Rigetti Computing (RGTI), WQTM’s second-largest component, is another example of a pure-play quantum name, with bellwether status in the group. In revenue terms, this is an early-stage company. If it makes progress on superconducting chiplets, though, it could be a key driver of long-term upside for WQTM.

D-Wave Quantum (QBTS), Infleqtion (INFQ), and Xanadu Quantum (XNDU), which combine for more than 11% of the WQTM roster, were also among the stocks with quantum purity mentioned by Gannatti in a recent note.

For more news, information, and analysis, visit the Modern Alpha Content Hub.

Disclosures This article was prepared as part of WisdomTree’s general paid sponsorship of VettaFi | ETF Trends. This specific content within and any opinions expressed therein belong solely to VettaFi and do not reflect the opinion or analysis of WisdomTree, its employees, or its affiliates. Content published on VettaFi | ETF Trends is provided for educational purposes only and should not be considered investment or tax advice. For investment or tax advice, please consult a financial professional. 

WisdomTree is an independent company, unaffiliated with VettaFi | ETF Trends. WisdomTree has not been involved with the preparation of the content supplied by VettaFi | ETF Trends. It does not guarantee, or assume any responsibility for its content.

Key Takeaways Quantinuum stock fell about 15% in a week after its record pure-play quantum computing IPO.Quantinuum raised $600M privately and $1.68B in its IPO, boosting its capital base.Quantinuum had $30.9M in 2025 revenues and incurred a roughly $193M net loss. Honeywell owns about 48%. Seven days after completing the largest pure-play quantum computing IPO on record, Honeywell (HON - Free Report) -backed Quantinuum's (QNT - Free Report) stock has lost roughly 15% of its value, falling from its $60 IPO price to around $51. The decline suggests that the market is moving beyond IPO enthusiasm and beginning to assess whether the company's long-term growth prospects justify its valuation.

For investors, this may be the right time to reassess the opportunity and determine whether the recent pullback offers an attractive entry point or signals a need for caution.

Image Source: Zacks Investment Research

How Quantinuum Compares With IonQ and D-WaveMore importantly, can Quantinuum replicate the wealth-creating trajectories witnessed in quantum computing leaders such as IonQ (IONQ - Free Report) and D-Wave Quantum (QBTS - Free Report) , or does its current valuation already reflect much of its future potential? Investors must now look beyond the post-IPO price action and assess whether Quantinuum's technological leadership and progress in commercialization are sufficient to justify its multi-billion-dollar valuation.

Like Quantinuum, both IONQ and QBTS stocks experienced significant volatility after going public. While D-Wave's shares struggled for an extended period before surging on renewed enthusiasm for quantum computing applications, IonQ gradually gained its position as the sector's benchmark through consistent technological progress, expanding customer relationships and growing commercial bookings.

Quantinuum, however, enters the public markets with advantages that neither IonQ nor D-Wave possessed at listing. Honeywell retains an approximately 48% stake in the company, providing strategic backing and financial stability.

Strong Capital Base Supports Long-Term Growth OutlookBeyond its technology, Quantinuum's capital position is perhaps one of its biggest competitive advantages. The company raised approximately $600 million in a private funding round in September 2025 at a $10 billion pre-money valuation, attracting investors like NVentures, JPMorganChase and Amgen. It then raised an additional $1.68 billion through its June 2026 IPO, giving it one of the strongest balance sheets among publicly traded quantum computing companies. The funding is expected to support continued technology development, commercialization efforts and the company's long-term goal of achieving universal fault-tolerant quantum computing.

Quantinuum also benefits from Honeywell's continued ownership stake and a growing ecosystem of strategic partnerships spanning NVIDIA, RIKEN, SoftBank and others. Unlike many emerging quantum companies that may eventually require additional financing to sustain operations, Quantinuum appears well-capitalized to execute its roadmap. The key challenge now is not access to capital, but converting its technological leadership and industry relationships into sustained revenue growth and broader commercial adoption.

Final TakeUnlike many emerging quantum computing companies that may eventually require additional financing to sustain operations, Quantinuum appears well-capitalized to execute its roadmap. However, investors should not overlook the valuation challenge. The company generated only $30.9 million in revenues in 2025 while reporting a net loss of roughly $193 million. As a result, the investment case ultimately hinges not on access to capital, but on Quantinuum's ability to translate its technological leadership, industry relationships and financial resources into sustained revenue growth and broader commercial adoption.

MINNEAPOLIS, April 01, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-ready Real-World Data (RWD), is pleased to announce that Inka Health, a wholly-owned subsidiary of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has entered into a collaboration with OneMedNet Inc., under which Onco-Innovations and Inka Health will have access to OneMedNet’s iRWD™ platform— powered by Palantir (PLTR) Foundry— providing it access to U.S. real-world oncology data. The agreement is intended to accelerate development timelines, reduce clinical and regulatory risk, and strengthen evidence generation for Onco-Innovations’ proprietary PNKP Inhibitor Technology targeting PTEN/SHP1-deficient cancers.

Under the agreement, Inka Health is gaining access to OneMedNet’s iRWD™ platform through a selective pilot program following technical evaluation and qualification. The collaboration will initially focus on applying real-world data and advanced analytics to support Onco’s PNKP Inhibitor Technology’s development strategy, including patient responder identification, indication expansion beyond advanced metastatic colorectal cancer, and complementary evidence generation to inform clinical and regulatory decision-making. Inka Health also intends to use OneMedNet’s iRWD™ platform to improve and further develop the core model of SynoGraph™, its causal-inference based AI platform that aims to predict the success and safety of potential new cancer treatments by analyzing multimodal medical data.

Importantly, this engagement reflects the original architectural intent of the iRWD™ platform: to enable rapid identification and characterization of rare and molecularly defined patient populations at scale. By combining multi-modal data, longitudinal clinical context, and AI-augmented search capabilities, the platform is purpose-built to locate hard-to-find cohorts, —such as PTEN/SHP1-deficient tumors—, and accelerate innovation in areas where traditional trial recruitment and evidence development can be challenging.

“This collaboration demonstrates exactly what our iRWD™ platform was designed to do—find and characterize rare, high-value patient populations to accelerate innovation,” said Aaron Green, CEO & President of OneMedNet. “By bringing together regulatory-grade real-world data, multi-modal clinical depth, and Palantir-powered AI, we can help oncology innovators de-risk development, move faster, and generate meaningful evidence in complex disease segments.”

“Access to high-quality U.S. oncology real-world data is a critical enabler for PNKP Inhibitor Technology,” said Thomas O’Shaunghnessy, CEO of Onco-Innovations. “This collaboration allows us to better understand real-world patient populations with PTEN/SHP1-deficient tumors, identify potential responders, and explore additional indications—, helping us de-risk development while improving capital efficiency for shareholders.”

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.

ON BEHALF OF ONCO-INNOVATIONS LIMITED,

“Thomas O’Shaughnessy”
Chief Executive Officer

For more information, please contact:

Thomas O’Shaughnessy

Chief Executive Officer

Tel: + 1 888 261 8055
[email protected]

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements.  These statements include, but are not limited to, statements regarding our products, plans and strategies, and our ability to achieve our operational strategies.

Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Digital Assets, including Digital Asset’s volatility; our ability to implement our Digital Asset treasury strategy and its effects on our business; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

OneMedNet Contacts:
Michael Wong, VP Marketing
Email: [email protected]

MINNEAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-Driven Real-World Data (RWD), today announced that its OneMedNet iRWD™ Platform, built on Palantir Foundry, is now live and fully operational. This major commercialization milestone delivers searchable access to billions of records across 80 million patient journeys in seconds, transforming how life sciences organizations access and analyze multi-modal clinical data at unprecedented scale and speed.

Key Commercial Milestones of iRWD™ Platform:

OneMedNet iRWD™ Platform Now Live on Palantir Foundry~70% increase in OneMedNet network, to 80 million patients and 251 million studies Creating what we believe is the industry's largest network of curated, multi-modal Real-World Data Creates access to approximately 47 million tokenized patients via Datavant Enables seamless linkage to complementary datasets including genomics, claims, and mortality data for deeper longitudinal insights Two new customers contracted for iRWD™ Platform "The integration of our iRWD™ platform with Palantir Foundry marks a transformative step for OneMedNet. Our subscription customers can now find the data they need in seconds — unlocking a new phase of commercial execution and significantly enhancing our ability to deliver high-value, decision-grade data. We are now actively converting a robust pipeline into subscription-based customers with meaningful annual recurring revenue potential." said Aaron Green, President & CEO of OneMedNet. "Most importantly, we've unlocked the patients our customers require: about 80 million patients on the network and 47 million tokenized patients on Datavant. We previously outlined this strategy, and we've now executed on it. By combining Palantir's powerful ontology and analytics capabilities with Datavant's tokenized linkage, we can deliver longitudinally connected, multimodal datasets that accelerate foundational AI model development and create durable, long-term value."

With the Palantir-powered iRWD™ platform now live and fully searchable, OneMedNet is executing its strategy of securing high-margin, annual recurring revenue (ARR) subscriptions. The Company believes the combination of the new platform capabilities and an expanding customer pipeline positions the Company to convert growing interest into meaningful revenue opportunities.

About OneMedNet Corporation

OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 2,130 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.

Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information.

Learn more at www.onemednet.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements.  These statements include, but are not limited to, statements regarding the expected benefits and demand to be driven by the integration of the completed iRWD™ platform, and statements generally about our products, plans and strategies, our expected growth in the business, and our ability to achieve our operational strategies.

Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Digital Assets, including Digital Asset’s volatility; our ability to implement our Digital Asset treasury strategy and its effects on our business; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

OneMedNet Contacts:
Michael Wong, VP Marketing
Email: [email protected]

SOURCE: ONEMEDNET CORPORATION

MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-Driven Real-World Data (RWD), today announced that its OneMedNet iRWD™ Network, has surpassed 90 million patient journeys and 270 million studies, with a healthcare partner network now exceeding 2,300 sites. The milestone represents direct progress against the strategic priorities the Company laid out to shareholders at the close of 2025, when OneMedNet identified expansion of its data network as a core pillar of long-term value creation. Today's announcement reflects the team's disciplined execution against that commitment – extending the breadth, depth, and connectivity of the network to meet accelerating demand for Real-World Data and AI foundational models.

Key Milestones:

More than 90 million patient journeys, a 12.5% increase since April 2026 in just two months, with 270 million studies available.Expanded provider network by more than 30% in less than a year, growing from approximately 1,750 to more than 2,300 healthcare partner sites.Encompasses hard to find data such as rare diseases, oncology, cardiology, and beyond.Increased specialized multi-modal data coverage across Radiology, Cardiology, EEG, ECG, and other diagnostic modalities, alongside de-identified electronic health records. “Surpassing 90 million patient journeys, 270 million studies, and 2,300 healthcare partner sites is exactly the kind of progress we told our shareholders to expect when we outlined our strategy at the end of 2025," said Aaron Green, President & CEO of OneMedNet. "Growing the network is a deliberate, central pillar of how we build durable value, and this milestone shows the team executing against that plan. Life sciences organizations, drug developers, and AI innovators increasingly require deeper, more diverse, and longitudinally connected datasets. By continuously expanding our provider partnerships and the breadth of our curated, multi-modal data, we are uniquely positioned to meet the needs of life sciences organizations, drug developers, and AI innovators — delivering durable, long-term value for our customers and shareholders."

About OneMedNet Corporation

OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 2,130 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.

Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information.

Learn more at www.onemednet.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements.  These statements include, but are not limited to, statements regarding the achievement of our strategies, , and statements generally about our products, plans and strategies.

Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Digital Assets, including Digital Asset’s volatility; our ability to implement our Digital Asset treasury strategy and its effects on our business; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

OneMedNet Contacts:

Michael Wong, VP Marketing

Email: [email protected]

SOURCE: ONEMEDNET CORPORATION

, /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that positive Phase II results from the COMPASSION-26 study evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy as first-line treatment for advanced pancreatic ductal adenocarcinoma (PDAC), were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

As of the October 20, 2025 data cutoff, with a median follow-up of more than two years, the cadonilimab plus chemotherapy combination continued to deliver robust and durable survival benefits. Results were particularly strong in patients with locally advanced disease, where the median PFS reached 11.1 months and the median OS exceeded 23 months. Landmark survival rates in this group included a 12-month OS rate of 91.7% and a 24-month OS rate of 44.1%.

The cadonilimab regimen also provided strong tumor control across the overall study population. Of the patients evaluable for efficacy (95% had at least one post-baseline tumor assessment), the objective response rate (ORR) was 33.9% and the disease control rate (DCR) reached 96.4%. Response rates were similar between patients with locally advanced and metastatic disease, indicating consistent benefit across both subgroups.

No new safety signals were identified, and the overall safety profile of the cadonilimab combination remained favorable and manageable.

Cadonilimab is the world's first approved bispecific antibody for cancer immunotherapy, having received marketing approval in 2022. In extensive real-world clinical practice and multiple Phase III studies, it has demonstrated clinically meaningful benefit across all patient populations regardless of PD-L1 expression status, addressing a significant unmet medical need and earning broad recognition from physicians and patients.

As a cornerstone therapy in the era of tumor immunotherapy 2.0, cadonilimab not only offers the significant advantage of clinical benefit across broad patient populations, but has also demonstrated important breakthrough potential in difficult-to-treat settings, including immunotherapy-refractory disease and immunologically "cold" tumors. Akeso is fully leveraging its global leadership in bispecific antibody development for oncology to continue addressing major unmet clinical needs and advancing transformative treatment options for patients with challenging cancers.

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient, integrated commercialization model, the company has evolved into a globally competitive biopharmaceutical focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 27 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

Forward-Looking Statements
This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

SOURCE Akeso, Inc.

, /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the Company's first-in-class PD-1/VEGF bispecific antibody, has achieved a statistically significant and clinically meaningful improvement in overall survival (OS) as a first-line treatment for patients with advanced squamous non-small cell lung cancer (sq-NSCLC) in the Phase III HARMONi-6 (AK112-306) study. These landmark findings will be featured in a Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Professor Shun Lu, Director of the Lung Cancer Center at Shanghai Chest Hospital and Principal Investigator of HARMONi-6, presented the data in an oral Plenary Session presentation.

This marks the first time a China-originated investigational oncology drug has been selected for the ASCO Plenary Session in the society's 61-year history. This moment is a definitive testament to the ivonescimab regimen's role in ushering cancer immunotherapy into the '2.0 Era'.

The HARMONi-6 study results were simultaneously published in The Lancet.

The HARMONi-6 study enrolled a total of 532 patients. Among them, approximately 63% had centrally located squamous tumors, 39.0% had PD-L1 TPS <1%, and 33.8% had multi-site metastases, liver metastases, or brain metastases. At the pre-specified interim analysis, as assessed by the Independent Data Monitoring Committee (IDMC), the study met its key secondary endpoint of overall survival (OS), demonstrating both clinically a meaningful and statistically significant benefit.

As of the data cutoff date of February 27, 2026, with a median follow-up of 21.36 months:

34% reduction in the risk of death - ivonescimab plus chemotherapy significantly prolonged OS

In the intent-to-treat (ITT) population, ivonescimab plus chemotherapy reduced the risk of death by 34% versus tislelizumab plus chemotherapy (HR=0.66 [95% CI: 0.50–0.87], P=0.0017(＜0.0049). Median OS was 27.9 months in the ivonescimab arm (the final death event in this arm caused the Kaplan-Meier curve to drop sharply to the median, thereby producing the mOS estimate) versus 23.7 months in the control arm. The 12-month OS rate was 78.9% with ivonescimab plus chemotherapy versus 72.2% in the control arm, and the 24-month OS rate was 64.7% versus 48.6%, respectively. The survival benefit continued to widen over time, reflecting a more durable and clinically meaningful long-term survival advantage. Consistent OS benefit across all prespecified subgroups

OS benefit with ivonescimab was observed consistently regardless of PD-L1 expression status: HR=0.68 in the PD-L1 TPS ≥1% subgroup and HR=0.64 in the TPS <1% subgroup; HR=0.67 in the PD-L1 TPS 1–49% subgroup and HR=0.64 in the TPS ≥50% subgroup. The OS benefit was also consistent across subgroups defined by metastatic burden: HR=0.47 in patients with ≥3 metastatic sites and HR=0.69 in those with liver metastases. Comparable subsequent anticancer therapy between the two arms

Proportions of patients in the two groups who subsequently received immunotherapy: 13.9% in the treatment group vs 19.2% in the control group; proportions receiving targeted therapy: 12.4% vs 17.3%; proportions receiving ADC therapy: 4.5% vs 5.6%; proportions participating in other clinical trials: 0.8% vs 2.3%.

Favorable safety profile comparable to tislelizumab plus chemotherapy

Grade ≥3 treatment-related adverse events (TRAEs) occurred in 69.2% of patients in the ivonescimab arm and 58.9% in the control arm. Rates of adverse events leading to treatment discontinuation or death were similar between arms. At the prespecified interim analysis for progression-free survival (PFS), ivonescimab plus chemotherapy had already demonstrated a clinically meaningful and statistically significant improvement in PFS compared with tislelizumab plus chemotherapy, with a median PFS of 11.1 months versus 6.9 months (HR=0.60 [95% CI: 0.46–0.78], P＜0.0001).

Professor Shun Lu, Principal Investigator of HARMONi-6, Director of the Lung Cancer Center at Shanghai Chest Hospital and Tenured Professor:

"HARMONi-6 is the first global Phase III study in lung cancer to show statistically significant improvements in both OS and PFS compared with PD-1 plus chemotherapy. It is also the first in sq-NSCLC to achieve dual OS and PFS success through a pre-specified hypothesis test. The results significantly reduced the risk of death and disease progression, with consistent benefits across all subgroups, while enabling patients to maintain better quality of life for longer.

These strong head-to-head data redefine the gold standard for first-line sq-NSCLC treatment and fill a major clinical gap for anti-angiogenic therapy in this setting. We look forward to ivonescimab delivering broader benefits to patients worldwide as a next-generation immuno-oncology therapy."

Dr. Yu Xia, Founder, Chairwoman, President and CEO of Akeso:

"Today, we are thrilled to announce that ivonescimab plus chemotherapy has successfully challenged PD-1 plus chemotherapy, achieving both clinically meaningful and statistically significant improvements in overall survival (OS) and progression-free survival (PFS). We extend our sincere gratitude to all investigators, clinical teams, and patients who participated in this study. Thanks to their efforts, Chinese patients with advanced sq-NSCLC are the first to benefit from this innovative, safe, and highly effective global therapy.

Prior to ivonescimab, no therapy had successfully challenged the dominance of PD-1-based regimens in a head-to-head Phase III trial. Ivonescimab has already demonstrated dual OS and PFS benefits in EGFR-mutant non-squamous NSCLC after TKI failure, becoming the first immunotherapy approved in this setting. It has also shown superior PFS versus pembrolizumab monotherapy in first-line PD-L1-positive NSCLC. These results have generated strong global anticipation for next-generation therapies. Since its launch, ivonescimab has been widely adopted by clinicians and patients.

PD-1 plus chemotherapy is currently the most broadly used first-line regimen in oncology. Following our previous success versus pembrolizumab monotherapy, the HARMONi-6 study now demonstrates for the first time that ivonescimab plus chemotherapy can achieve dual superiority in both OS and PFS over PD-1 plus chemotherapy. This landmark result solidifies ivonescimab's position as a next-generation cornerstone of cancer immunotherapy.

The success of HARMONi-6 gives us even greater confidence to leverage global resources, fully unlock ivonescimab's potential, reshape treatment paradigms, and deliver more effective and safer solutions to patients worldwide."

Ivonescimab is currently being evaluated in more than 30 clinical settings across a wide range of tumors, including 15 Phase III trials, seven of which are head-to-head studies versus PD-1/PD-L1 therapies. The positive results from HARMONi-6 further strengthen its differentiated clinical profile. In partnership with Summit Therapeutics, Akeso remains fully committed to advancing the global development of ivonescimab to maximize its therapeutic benefit for patients worldwide.

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient, integrated commercialization model, the company has evolved into a globally competitive biopharmaceutical focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 27 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

Forward-Looking Statements

This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

SOURCE Akeso, Inc.

Reshoring is the macroeconomic theme of the United States, bringing industrial capacity from Asia (specifically China) back home to North and South America. Some manufacturing will be done in the United States (e.g., semiconductors), while some will flow to other nations.

No country is better positioned to benefit from reshoring than Mexico. But how does one invest to take advantage of the potential economic boom south of the border? The answer may lie in the aviation sector and the publicly traded airport stocks in Mexico.

Image source: Getty Images.

Grupo Aeroportuario del Pacífico: Betting on Mexican tourism Unlike in the United States, the operators of Mexican airports are publicly traded companies, of which there are three. They don't own the airport but have long-term (generally 50-year) contracts that allow them to manage these assets for the government while splitting the profits.

Grupo Aeroportuario del Pacífico (PAC +3.79%) is one of Mexico's airport operators, focused on the Pacific region, with its largest airports being in Guadalajara, Los Cabos, Tijuana, and Puerto Vallarta. These cities have a mix of international tourism and industrial capacity, with Tijuana benefiting from a land bridge connecting to San Diego that allows residents to easily get on cheaper flights when visiting Mexico.

The stock is trading down 15% from its highs due to fears over recent cartel violence in Mexico, which seems to have subsided for the time being, as well as global concerns about rising oil prices and their potential impact on air travel demand.

Airport operators such as Grupo Pacifico make money as more passengers flow through their airports, along with government-allowed price increases. Over the long term, air traffic to Mexico has exploded because of international tourism, general economic growth in Mexico, and growing industrial capacity in places such as Guadalajara, which drives business travel.

NYSE: PACGrupo Aeroportuario Del PacíficoB. De C.v.

Today's Change

(

3.79

%) $

8.41

Current Price

$

230.15

Right now, the stock trades at a dividend yield of 3.5% and at 13 times its trailing EBITDA (earnings before interest, taxes, depreciation, and amortization). This is for a business that has grown its revenue by 286% over the past 10 years in U.S. dollar terms, despite a global pandemic in between. Unless you think Mexican tourism is going to fall apart overnight, now could be a great time to buy Grupo Pacifico stock.

Grupo Aeroportuario del Centro Norte: The reshoring focus The airport operator most focused on the reshoring theme is Grupo Aeroportuario del Centro Norte (OMAB +3.33%), which operates the Monterrey airport and a number of smaller regional airports across Mexico's North and Western regions.

Today's Change

(

3.33

%) $

3.19

Current Price

$

99.11

Monterrey is the wealthiest large city in Mexico and is closest to the United States. It has become wealthier than the average Mexican metro area because of its industrial might, with many companies around the world setting up shop there to ship goods to the United States. It even offers direct flights to Tokyo and Seoul to serve electronic manufacturing companies in the area.

It lacks the tourist charm, but Monterrey will benefit if the reshoring trend continues through the rest of this decade. Total passenger traffic grew 8.5% year over year in 2025, with Monterrey growing 15% and making up around half of passenger volume. Right now, the stock trades at a dividend yield of 4.2% and 11.5 times EBITDA, making it even cheaper than Grupo Pacifico.

Data by YCharts.

Should you buy Mexican airport stocks? If you have only invested in your home market, it might feel scary to buy a stock from a country like Mexico, where you have less understanding of the local culture and economy. This fear may be warranted for consumer goods, but airports are very similar, no matter which country you go to.

Currency risks are another factor that pops up, but they can be mitigated by increasing per-passenger fees and by international traffic and commercial revenue from tourism shops. As a monopoly, the Mexican government regulates airports and determines the prices inbound flights can charge, with Grupo Norte granted the right to increase prices by 38% over the next five years. That sounds like a good business to me.

Mexican airport stocks are well-positioned to deliver strong returns for shareholders over the next decade.

GUADALAJARA, Mexico, April 20, 2026 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) reports its consolidated results for the first quarter ended March 31, 2026 (1Q26). Figures are unaudited and prepared following International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). The results reported herein do not reflect the pending business combination approved at the Extraordinary General Shareholders’ Meeting held on December 11, 2025, which contemplates the integration of the Cross Border Xpress (“CBX”) and the internalization of the technical assistance services provided by AMP. Definitive transaction agreements have not yet been executed, and consummation remains subject to customary closing conditions.

Summary of Results 1Q26 vs. 1Q25

The sum of aeronautical and non-aeronautical services revenues increased by Ps. 380.9 million, or 4.5%. Total revenues increased by Ps. 314.4 million, or 2.8%.
Cost of services increased by Ps. 94.5 million, or 6.5%.
Income from operations increased by Ps. 359.7 million, or 7.7%.
EBITDA increased by Ps. 360.0 million, or 6.4%, an increase from Ps. 5,628.8 million in 1Q25 to Ps. 5,988.8 million in 1Q26. EBITDA margin (excluding the effects of IFRIC-12) went from 67.1% in 1Q25 to 68.3% in 1Q26.
Comprehensive income increased by Ps. 551.4 million, or 19.6%, from an income of Ps. 2,814.4 million in 1Q25 to an income of Ps. 3,365.8 million in 1Q26. Company’s Financial Position:

During 1Q26, total aeronautical revenues increased compared to 1Q25, primarily driven by the airports in Mexico. This growth was partially offset by lower passenger traffic in Jamaica, where the impact of Hurricane Melissa in 4Q25 continued to weigh on the recovery of hotel capacity along the tourist corridor between Negril and Ocho Ríos; as a result, passenger traffic has not yet fully recovered.

In Mexico, security-related events in the state of Jalisco during February 2026 led to temporary disruptions in mobility and affected travel demand to certain destinations. In this context, Guadalajara and Puerto Vallarta airports presented passenger traffic decreases in March 2026 compared to March 2025.

In 1Q26, GAP issued bond certificates for a total amount of Ps.10,718.0 million under the ticker symbols “GAP 26” and “GAP 26-2,” for Ps.2,767.0 million and Ps.7,951.0 million, respectively. Proceeds will be used to acquire a 25% stake in CBX, as well as to finance capital expenditures in line with the 2025–2029 Master Development Program.

Additionally, the Company refinanced its existing loans with Scotiabank and BBVA for USD$95.5 million each through new financing with The Bank of Nova Scotia and BBVA, respectively. The Company also repaid bond certificates for a total amount of Ps.1,120.0 million (ticker symbol “GAP 23L”) using proceeds from a new bank loan with Scotiabank for the same amount.

As of March 31, 2026, the Company reported a cash and cash equivalents position of Ps.23,185.1 million.

Passenger Traffic

During 1Q26, the 14 airports operated by GAP recorded a decrease of 902.1 thousand total passengers, representing a 5.5% decrease compared to 1Q25.

During this period, the following new routes were inaugurated:

Domestic

 AirlineDepartureArrivalOpening dateFrequencies  VolarisGuadalajaraMazatlanMarch 29, 20263 weekly   AerusMoreliaSanta LuciaMarch 30, 20265 weekly   AerusMoreliaUruapanMarch 30, 20265 weekly           Note: Frequencies can vary without prior notice.
           International       AirlineDepartureArrivalOpening dateFrequencies  SouthwestPuerto VallartaSan DiegoMarch 5, 20261 daily   SouthwestLos CabosIndianapolisMarch 7, 20261 weekly   SouthwestMontego BayNashvilleMarch 7, 20261 weekly   SouthwestPuerto VallartaSt. LouisMarch 21, 20261 weekly           Note: Frequencies can vary without prior notice.   Domestic Terminal Passengers – 14 airports (in thousands):

Airport1Q251Q26ChangeGuadalajara3,021.13,035.60.5%Tijuana*2,057.51,968.5(4.3%)Los Cabos668.9628.3(6.1%)Puerto Vallarta653.6644.8(1.4%)Montego Bay0.00.0N/AGuanajuato515.5510.8(0.9%)Hermosillo508.7480.6(5.5%)Kingston0.10.7821.1%Morelia186.1192.83.6%La Paz280.6313.811.8%Mexicali293.1257.7(12.1%)Aguascalientes151.8138.9(8.5%)Los Mochis165.0163.3(1.1%)Manzanillo34.832.7(5.9%)Total8,536.98,368.5(2.0%)        International Terminal Passengers – 14 airports (in thousands): Airport1Q251Q26ChangeGuadalajara1,507.01,492.1(1.0%)Tijuana*1,014.9897.6(11.6%)Los Cabos1,382.91,372.7(0.7%)Puerto Vallarta1,472.51,278.9(13.1%)Montego Bay1,338.9917.4(31.5%)Guanajuato263.1257.8(2.0%)Hermosillo20.922.04.9%Kingston428.0414.8(3.1%)Morelia174.2215.623.7%La Paz8.712.644.5%Mexicali1.81.83.2%Aguascalientes73.777.34.9%Los Mochis1.91.8(3.1%)Manzanillo43.936.3(17.4%)Total7,732.56,998.7(9.5%)*CBX users are classified as international passengers.           Total Terminal Passengers – 14 airports (in thousands): Airport1Q251Q26ChangeGuadalajara4,528.24,527.8(0.0%)Tijuana*3,072.32,866.1(6.7%)Los Cabos2,051.82,001.0(2.5%)Puerto Vallarta2,126.11,923.7(9.5%)Montego Bay1,338.9917.4(31.5%)Guanajuato778.6768.7(1.3%)Hermosillo529.6502.5(5.1%)Kingston428.1415.5(2.9%)Morelia360.3408.313.3%La Paz289.3326.412.8%Mexicali294.9259.6(12.0%)Aguascalientes225.5216.2(4.1%)Los Mochis166.9165.1(1.1%)Manzanillo78.769.0(12.3%)Total16,269.315,367.2(5.5%) 1,767.01,332.9-24.6% 14,502.314,034.3-3.2%*CBX users are classified as international passengers.       CBX Users (in thousands):   Airport1Q251Q26ChangeTijuana998.2886.3(11.2%)    
Consolidated Results for the First Quarter of 2026 (in thousands of pesos): 

         1Q251Q26Change  Revenues     Aeronautical services5,999,133 6,234,471 3.9%  Non-aeronautical services2,393,875 2,539,478 6.1%  Improvements to concession assets (IFRIC-12)2,662,175 2,595,679 (2.5%)  Total revenues11,055,183 11,369,627 2.8%   8,393,008 8,773,948 4.5%  Operating costs     Costs of services:1,457,089 1,551,571 6.5%  Employee costs613,362 684,224 11.6%  Maintenance256,903 260,763 1.5%  Safety, security & insurance215,207 233,405 8.5%  Utilities125,231 125,013 (0.2%)  Business operated directly by us87,336 89,528 2.5%  Other operating expenses159,050 158,638 (0.3%)        Technical assistance fees283,900 299,542 5.5%  Concession taxes1,048,916 947,078 (9.7%)  Depreciation and amortization932,575 932,957 0.0%  Cost of improvements to concession assets (IFRIC-12)2,662,175 2,595,679 (2.5%)  Other (income)(25,683)(13,071)(49.1%)  Total operating costs6,358,972 6,313,756 (0.7%)  Income from operations4,696,211 5,055,871 7.7%  Financial Result(929,490)(723,258)(22.2%)  Income before income taxes 3,766,721 4,332,613 15.0%  Income taxes(908,605)(1,020,605)12.3%  Net income 2,858,115 3,312,008 15.9%  Currency translation effect(75,058)35,121 (146.8%)   Cash flow hedges, net of income tax(776)- (100.0%)  Remeasurements of employee benefit – net income tax32,099 18,642 (41.9%)  Comprehensive income 2,814,380 3,365,771 19.6%  Non-controlling interest(114,926)(138,515)20.5%  Comprehensive income attributable to controlling interest2,699,454 3,227,255 19.6%               1Q251Q26Change  EBITDA5,628,786 5,988,828 6.4%  Comprehensive income2,814,380 3,365,771 19.6%  Comprehensive income per share (pesos)5.5700 6.6612 19.6%  Comprehensive income per ADS (US dollars)3.0888 3.6940 19.6%        Operating income margin42.5%44.5%4.7%  Operating income margin (excluding IFRIC-12)56.0%57.6%3.0%  EBITDA margin50.9%52.7%3.5%  EBITDA margin (excluding IFRIC-12)67.1%68.3%1.8%  Costs of services and improvements / total revenues37.5%36.5%(2.8%)  Cost of services / total revenues (excluding IFRIC-12)17.7%17.7%(0.0%)              - Net income and comprehensive income per share for 1Q26 and 1Q25 were calculated based on 505,277,464 shares outstanding as of March 31, 2026, and March 31, 2025, respectively. Figures in U.S. dollar were converted from pesos using an exchange rate of Ps. 18.0327 per U.S. dollar, as published by the U.S. Federal Reserve Board (noon buying rate) on March 31, 2026.

- For consolidating the Jamaican airports, an average exchange rate of Ps. 17.5578 per U.S. dollar was used, corresponding to the three-month period ended March 31, 2026.

Revenues (1Q26 vs. 1Q25)

•   Aeronautical services revenues increased by Ps. 235.3 million, or 3.9%.
•   Non-aeronautical services revenues increased by Ps. 145.6 million, or 6.1%.
•   Revenues from improvements to concession assets decreased by Ps. 66.5 million, or 2.5%.
•   Total revenues increased by Ps. 314.4 million, or 2.8%.

The change in aeronautical services revenues was primarily due to the following factors:

Revenues at the Mexican airports increased by Ps. 472.9 million, or 9.3%, compared to 1Q25. This increase was mainly driven the phased implementation in 2025 of the new airport maximum tariffs approved for the 2025–2029 regulatory period.
Revenues at the Jamaican airports decreased by Ps. 237.6 million, or 26.2%, compared to 1Q25, mainly due to a 24.6% decrease in passenger traffic during the quarter, resulting from the impact of the Hurricane Melissa, as previously described. Additionally, the 14.0% appreciation of the Mexican peso against the U.S. dollar negatively affected revenue translation. In U.S. dollar terms, revenues decreased by US$6.3 million, or 16.4%.
The change in non-aeronautical services revenues was primarily driven by the following factors:

Revenues at Mexican airports increased by Ps. 222.6 million, or 10.7%, compared to 1Q25. Revenues from businesses operated directly by us increased by Ps. 199.8 million, or 19.9%. Revenues from businesses operated by third parties increased Ps. 22.2 million, or 2.2%. The fastest-growing business lines were food and beverage and car rental, which together increased by Ps. 33.9 million, or 7.0%. This increase was partially offset by a decrease in duty-free revenues, which declined Ps. 10.5 million, or 8.7%, due to the 14.0% appreciation of the Mexican peso.
Revenues at the Jamaican airports decreased by Ps. 76.9 million, or 24.7%, compared to 1Q25, primarily due to the decline in passenger traffic and the peso appreciation in the 1Q26. In U.S. dollar terms, revenues decreased by US$1.8 million, or 14.2%.
  1Q251Q26Change  Businesses operated by third parties:     Food and beverage342,580351,2942.5%  Car rental205,297212,5733.5%  Duty-free216,685182,533(15.8%)  Retail191,173183,349(4.1%)  Leasing of space116,904104,286(10.8%)  Timeshares70,90562,607(11.7%)  Ground transportation56,57353,188(6.0%)  Other commercial revenues72,02574,6783.7%  Communications and financial services31,39030,083(4.2%)  Total1,303,5321,254,591(3.8%)        Businesses operated directly by us:     Cargo operation and bonded warehouse434,269547,55126.1%  Car parking178,470191,9047.5%  Convenience stores169,500190,66112.5%  VIP Lounges168,016162,301(3.4%)  Advertising34,84039,69513.9%  Hotel operation37,44147,31926.4%  Access control services-39,332100.0%  Total1,022,5361,218,76319.2%  Recovery of costs67,80866,125(2.5%)  Total Non-aeronautical Revenues 2,393,8752,539,4796.1%        Figures expressed in thousands of Mexican pesos.

‐        Revenues from improvements to concession assets1

Revenues from improvements to concession assets (IFRIC-12) decreased by Ps. 66.5 million, or 2.5%, compared to 1Q25. The change was composed of:

Improvements to concession assets at the Company’s Mexican airports, decreased by Ps. 171.8 million, or 6.6%, in line with the investments committed under the Master Development Program for the 2025–2029 period.
Improvements to concession assets at the Company’s Jamaican airports, which increased by Ps. 105.3 million, or 154.9%. 1 Revenues from improvements to concession assets are recognized in accordance with International Financial Reporting Interpretation Committee 12 “Service Concession Arrangements” (IFRIC 12). However, this recognition does not have a cash impact or impact on the Company’s operating results. Amounts included as a result of the recognition of IFRIC 12 are related to construction of infrastructure in each quarter to which the Company has committed. This is in accordance with the Company’s Master Development Programs in Mexico and Capital Development Programs in Jamaica. All margins and ratios calculated using “Total Revenues” include revenues from improvements to concession assets (IFRIC 12), and, consequently, such margins and ratios may not be comparable to other ratios and margins, such as EBITDA margin, operating margin or other similar ratios that are calculated based on those results of the Company that do have a cash impact.

Total operating costs decreased by Ps. 45.2 million, or 0.7%, compared to 1Q25, mainly due to a decrease of Ps. 101.8 million, or 9.7%, in concession fees, and the cost of improvements to concession assets (IFRIC-12) of Ps. 66.5 million, or 2.5%. This effect was partially offset by an increase in the cost of services of Ps. 94.5 million, or 6.5%, and higher technical assistance fees of Ps. 15.6 million, or 5.5%. Excluding the cost of improvements to concession assets (IFRIC-12), operating costs increased by Ps. 21.3 million, or 0.6%, compared to 1Q25.

This increase in total operating costs was primarily due to the following factors:

   Mexican airports:

Operating costs increased by Ps. 50.3 million, or 0.9%, compared to 1Q25, mainly due to higher technical assistance and concession fees, which together increased by Ps. 96.5 million, or 11.4%; a Ps. 116.8 million, or 9.6%, increase in the cost of services; a Ps. 14.1 million, or 1.8%, increase in depreciation and amortization. This effect was partially offset by a Ps. 171.8 million, or 6.6%, decrease in the cost of improvements to the concession assets (IFRIC-12). Excluding the cost of improvements to concession assets (IFRIC-12), operating costs increased by Ps. 240.1 million, or 8.5%.
The change in the cost of services at our Mexican airports during 1Q26 was mainly due to:

Employee costs increased by Ps. 74.6 million, or 13.6%, mainly due to an increase in personnel, salary adjustments, and amendments to the Federal Labor Law.Safety, security, and insurance increased by Ps. 28.8 million, or 19.3%, mainly due to an increase in security personnel headcount and significant increases in the minimum wage.Maintenance increased by Ps. 17.6 million, or 8.7%, compared to 1Q25, mainly due to the opening of new operational areas, and airfield maintenance.
Jamaican Airports:

Operating expenses decreased by Ps. 95.5 million, or 10.2%, compared to 1Q25, mainly due to a reduction in concession fees of Ps. 155.0 million, or 33.7%; cost of services of Ps. 32.0 million, or 12.7%; and depreciation and amortization of Ps. 13.7 million, or 8.9%, driven by the decline in passenger traffic and the 14.0% appreciation of the Mexican peso against the U.S. dollar. This effect was partially offset by an increase in the cost of improvements to concession assets (IFRIC-12) of Ps. 105.3 million, or 154.9%.
Operating income margin increased from 42.5% in 1Q25 to 44.5% in 1Q26. Excluding the effects of IFRIC-12, the operating income margin increased from 56.0% in 1Q25 to 57.6% in 1Q26. Income from operations increased by Ps. 359.7 million, or 7.7%, compared to 1Q25.

EBITDA margin went from 50.9% in 1Q25 to 52.7% in 1Q26. Excluding the effects of IFRIC-12, EBITDA margin went from 67.1% in 1Q25 to 68.3% in 1Q26. The nominal value of EBITDA increased by Ps. 360.0 million, or 6.4%, compared to 1Q25.

Financial results decreased expenses by Ps. 206.2 million, or 22.2%, going from a net expense of Ps. 929.5 million in 1Q25 to a net expense of Ps. 723.3 million in 1Q26. This change was mainly the result of:

Foreign exchange rate fluctuations, which changed from a loss of Ps. 123.9 million in 1Q25 to a gain of Ps. 173.4 million in 1Q26, resulting in a foreign exchange gain of Ps. 297.3 million due to the appreciation of the Mexican peso. Additionally, the foreign currency translation effect recorded a gain compared to the foreign exchange loss in 1Q25, resulting in a net gain of Ps. 110.2 million.
Interest expense decreased by Ps. 66.0 million, or 5.7%, compared to 1Q25, mainly due to a decrease in reference rates.
Interest income decreased by Ps. 157.1 million, or 47.2%, compared to 1Q25, mainly due to a decrease in the cash and cash equivalents average balance and decrease in the reference rates.
In 1Q26, net and comprehensive income increased by Ps. 551.4 million, or 19.6%, compared to 1Q25, mainly driven by income before taxes, which increased by Ps. 565.9 million or 15.0%.

Net income increased by Ps. 453.9 million, or 15.9%, compared to 1Q25. Income tax for the period increased by Ps. 112.0 million, or 12.3%, comprised of an increase in current income tax of Ps. 95.2 million and a decrease in the deferred tax benefit of Ps. 16.8 million.

Statement of Financial Position

As of March 31, 2026, total assets increased by Ps. 16,288.8 million compared to the same period in 2025, mainly due to: (i) an increase in cash and cash equivalents of Ps. 6,957.0 million, (ii) an increase in improvements to concession assets of Ps. 4,962.1 million; (iii) an increase in construction in progress of Ps. 2,723.9 million; (iv) an increase in advanced payments to suppliers of Ps. 2,167.8 million; and (v) an increase in deferred income taxes of Ps. 649.9 million. This effect was partially offset by a decrease in (i) airport concessions of Ps. 873.4 million and (ii) other acquired rights of Ps. 275.3 million, among others.

As of March 31, 2026, total liabilities increased by Ps. 15,523.2 million compared to the same period in 2025. This increase was mainly attributable to: (i) an increase in bond certificates of Ps. 15,598.0 million; (ii) security deposits received of Ps. 135.4 million. This effect was partially offset by decreases in (i) deferred income taxes of Ps. 523.3 million and (ii) rights over concession assets of Ps. 272.2 million, among others.

Company Description

Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (GAP) operates 12 airports throughout Mexico’s Pacific region, including the major cities of Guadalajara and Tijuana, the four tourist destinations of Puerto Vallarta, Los Cabos, La Paz and Manzanillo, and six other mid-sized cities: Hermosillo, Guanajuato, Morelia, Aguascalientes, Mexicali, and Los Mochis. In February 2006, GAP’s shares were listed on the New York Stock Exchange under the ticker symbol “PAC” and on the Mexican Stock Exchange under the ticker symbol “GAP”. In April 2015, GAP acquired 100% of Desarrollo de Concesiones Aeroportuarias, S.L., which owns a majority stake in MBJ Airports Limited, a company operating Sangster International Airport in Montego Bay, Jamaica. In October 2018, GAP entered into a concession agreement for the Norman Manley International Airport operation in Kingston, Jamaica, and took control of the operation in October 2019.

This press release contains references to EBITDA, a financial performance measure not recognized under IFRS and which does not purport to be an alternative to IFRS measures of operating performance or liquidity. We caution investors not to place undue reliance on non-GAAP financial measures such as EBITDA, as these have limitations as analytical tools and should be considered as a supplement to, not a substitute for, the corresponding measures calculated in accordance with IFRS. This press release may contain forward-looking statements. These statements are statements that are not historical facts and are based on management’s current view and estimates of future economic circumstances, industry conditions, company performance, and financial results. The words “anticipates”, “believes”, “estimates”, “expects”, “plans” and similar expressions, as they relate to the company, are intended to identify forward-looking statements. Statements regarding the declaration or payment of dividends, the implementation of principal operating and financing strategies and capital expenditure plans, the direction of future operations, and the factors or trends affecting financial condition, liquidity, or results of operations are examples of forward-looking statements. Such statements reflect the current views of management and are subject to a number of risks and uncertainties. There is no guarantee that the expected events, trends, or results will occur. The statements are based on many assumptions and factors, including general economic and market conditions, industry conditions, and operating factors. Any changes in such assumptions or factors could cause actual results to differ materially from current expectations.

In accordance with Section 806 of the Sarbanes-Oxley Act of 2002 and Article 42 of the “Ley del Mercado de Valores”, GAP has implemented a “whistleblower” program, which allows complainants to anonymously and confidentially report suspected activities that involve criminal conduct or violations. The telephone number in Mexico, facilitated by a third party responsible for collecting these complaints, is 800 04 ETICA (38422) or WhatsApp +52 55 6538 5504. The website is www.lineadedenunciagap.com or by email at [email protected]. GAP’s Audit Committee will be notified of all complaints for immediate investigation.

Exhibit A: Operating results by airport (in thousands of pesos):

Airport1Q251Q26Change Guadalajara    Aeronautical services1,589,0871,771,98811.5% Non-aeronautical services360,536388,7247.8% Improvements to concession assets (IFRIC 12)1,174,4261,118,313(4.8%) Total Revenues3,124,0493,279,0255.0% Operating income1,182,2311,367,58915.7% EBITDA1,394,1021,580,73913.4%      Tijuana    Aeronautical services732,814824,93112.6% Non-aeronautical services124,721133,6937.2% Improvements to concession assets (IFRIC 12)386,094453,86617.6% Total Revenues1,243,6291,412,48913.6% Operating income406,403485,37919.4% EBITDA532,938613,26215.1%      Los Cabos    Aeronautical services946,6321,036,5929.5% Non-aeronautical services362,666345,845(4.6%) Improvements to concession assets (IFRIC 12)205,863212,8633.4% Total Revenues1,515,1611,595,2995.3% Operating income838,814884,8715.5% EBITDA935,852990,0375.8%      Puerto Vallarta    Aeronautical services988,172997,9271.0% Non-aeronautical services187,583189,3390.9% Improvements to concession assets (IFRIC 12)503,536410,908(18.4%) Total Revenues1,679,2911,598,175(4.8%) Operating income781,159794,8401.8% EBITDA846,378857,0341.3%      Montego Bay    Aeronautical services585,365347,867(40.6%) Non-aeronautical services244,588178,341(27.1%) Improvements to concession assets (IFRIC 12)48,98648,363(1.3%) Total Revenues878,940574,571(34.6%) Operating income342,516212,907(37.8%) EBITDA432,334295,583(31.6%)      
Exhibit A: Operating results by airport (in thousands of pesos):

Airport1Q251Q26Change Guanajuato    Aeronautical services268,399294,2329.6% Non-aeronautical services50,63745,809(9.5%) Improvements to concession assets (IFRIC 12)130,22273,383(43.6%) Total Revenues449,258413,424(8.0%) Operating income199,152210,2055.6% EBITDA225,070241,2867.2%      Hermosillo    Aeronautical services143,349153,1526.8% Non-aeronautical services26,57126,9811.5% Improvements to concession assets (IFRIC 12)17,2245,657(67.2%) Total Revenues187,144185,790(0.7%) Operating income78,35384,9818.5% EBITDA104,683110,5805.6%      Others (1)    Aeronautical services745,314807,7808.4% Non-aeronautical services118,544111,955(5.6%) Improvements to concession assets (IFRIC 12)195,823272,32539.1% Total Revenues1,059,6811,192,06012.5% Operating income232,157283,66922.2% EBITDA337,204384,90614.1%      Total     Aeronautical services5,999,1326,234,4703.9% Non-aeronautical services1,475,8451,420,686(3.7%) Improvements to concession assets (IFRIC 12)2,662,1752,595,679(2.5%) Total Revenues10,137,15110,250,8351.1% Operating income4,060,7824,324,4416.5% EBITDA4,808,5625,073,4265.5%       (1)    Others include the operating results of the Aguascalientes, La Paz, Los Mochis, Manzanillo, Mexicali, Morelia, and Kingston airports.

Exhibit B: Consolidated statement of financial position as of March 31 (in thousands of pesos): 

  2025
2026
Change %  Assets      Current assets      Cash and cash equivalents16,227,819 23,185,136 6,957,317 42.9%  Trade accounts receivable - Net3,328,186 3,410,039 81,853 2.5%  Other current assets1,196,602 1,227,344 30,742 2.6%  Total current assets20,752,607 27,822,519 7,069,912 34.1%         Advanced payments to suppliers926,353 3,094,180 2,167,827 234.0%  Machinery, equipment and improvements to leased buildings - Net4,657,478 4,442,717 (214,761)(4.6%)  Improvements to concession assets - Net25,186,205 30,148,259 4,962,054 19.7%  Construction in-progress11,760,860 14,484,845 2,723,985 23.2%  Airport concessions - Net9,515,482 8,642,096 (873,386)(9.2%)  Rights to use airport facilities - Net979,700 929,550 (50,150)(5.1%)  Other acquired rights2,005,950 1,730,620 (275,330)(13.7%)  Deferred income taxes - Net8,361,180 9,011,049 649,869 7.8%  Other non-current assets86,633 215,438 128,805 148.7%  Total assets84,232,447 100,521,273 16,288,826 19.3%         Liabilities       Current liabilities12,333,203 18,607,185 6,273,982 50.9%  Long-term liabilities44,463,118 53,712,376 9,249,258 20.8%  Total liabilities56,796,322 72,319,562 15,523,240 27.3%         Stockholders' Equity      Common stock1,194,390 1,194,390 - 0.0%  Legal reserve920,187 238,878 (681,309)(74.0%)  Retained earnings19,705,850 21,873,663 2,167,813 11.0%  Reserve for share repurchase2,500,000 2,500,000 - 0.0%  Foreign currency translation reserve689,812 (145,739)(835,551)(121.1%)  Remeasurements of employee benefit – Net40,382 36,524 (3,858)(9.6%)  Cash flow hedges- Net(5,361)- 5,361 (100.0%)  Total controlling interest25,045,260 25,697,716 652,456 2.6%  Non-controlling interest2,390,866 2,503,995 113,129 4.7%  Total stockholder's equity27,436,126 28,201,711 765,585 2.8%         Total liabilities and stockholders' equity84,232,447 100,521,273 16,288,826 19.3%         The non-controlling interest corresponds to the 25.5% stake held in the Montego Bay airport by Vantage Airport Group Limited (“Vantage”), as well as the 48.5% held by the shareholders of GWTC.

Exhibit C: Consolidated statement of cash flows (in thousands of pesos):

  1Q251Q26Change Cash flows from operating activities:    Consolidated net income2,858,116 3,312,008 15.9%      Postemployment benefit costs14,161 20,508 44.8% Allowance expected credit loss25,392 21,402 (15.7%) Depreciation and amortization932,575 932,957 0.0% Loss (gain) on sale of machinery, equipment and improvements to leased assets1,989 (1,669)(183.9%) Interest expense1,247,253 1,020,739 (18.2%) Provisions(30,688)34,307 (211.8%) Income tax expense908,605 1,020,605 12.3% Unrealized exchange loss110,879 (122,546)(210.5%)  6,068,282 6,238,311 2.8% Changes in working capital:    (Increase) decrease in    Trade accounts receivable(656,044)69,230 (110.6%) Recoverable tax on assets and other assets81,639 63,015 (22.8%) Increase (decrease)    Concession taxes payable33,274 224,240 573.9% Accounts payable71,452 2,110,894 2854.3% Cash generated by operating activities5,598,603 8,705,690 55.5% Income taxes paid(1,122,042)(1,133,849)1.1% Net cash flows provided by operating activities4,476,561 7,571,841 69.1%      Cash flows from investing activities:    Machinery, equipment and improvements to concession assets(1,706,642)(1,757,612)3.0% Cash flows from sales of machinery and equipment118 1,559 1221.2% Other investment activities13,822 (113,150)(918.6%) Net cash used by investment activities(1,692,702)(1,869,203)10.4%           Bond certificates issued6,000,000 10,718,000 78.6% Bond certificates paid(4,500,000)(1,120,000)(75.1%) Bank loans paid- (4,498,971)100.0% Bank loans- 3,378,971 100.0% Interest paid on bank loans(1,365,386)(1,361,703)(0.3%) Interest paid on lease(690)(2,778)302.6% Payments of obligations for leasing(16,332)(10,557)(35.4%) Net cash flows used in financing activities117,592 7,102,962 5940.3%      Effects of exchange rate changes on cash held(139,660)(73,662)(47.3%) Net increase (decrease) in cash and cash equivalents2,761,791 12,731,938 361.0% Cash and cash equivalents at beginning of the period13,466,026 10,453,198 (22.4%) Cash and cash equivalents at the end of the period16,227,819 23,185,136 42.9%           Exhibit D: Consolidated statements of profit or loss and other comprehensive income (in thousands of pesos):

 Consolidated Results for the First Quarter of 2025 (thousands)      1Q251Q26Change  Revenues     Aeronautical services5,999,133 6,234,471 3.9%  Non-aeronautical services2,393,875 2,539,478 6.1%  Improvements to concession assets (IFRIC-12)2,662,175 2,595,679 (2.5%)  Total revenues11,055,183 11,369,627 2.8%        Operating costs     Costs of services:1,457,089 1,551,571 6.5%  Employee costs613,362 684,224 11.6%  Maintenance256,903 260,763 1.5%  Safety, security & insurance215,207 233,405 8.5%  Utilities125,231 125,013 (0.2%)  Business operated directly by us87,336 89,528 2.5%  Other operating expenses159,050 158,638 (0.3%)        Technical assistance fees283,900 299,542 5.5%  Concession taxes1,048,916 947,078 (9.7%)  Depreciation and amortization932,575 932,957 0.0%  Cost of improvements to concession assets (IFRIC-12)2,662,175 2,595,679 (2.5%)  Other (income)(25,683)(13,071)(49.1%)  Total operating costs6,358,972 6,313,756 (0.7%)  Income from operations4,696,211 5,055,871 7.7%  Financial Result(929,490)(723,258)(22.2%)  Income before income taxes 3,766,721 4,332,613 15.0%  Income taxes(908,605)(1,020,605)12.3%  Net income 2,858,115 3,312,008 15.9%  Currency translation effect(75,058)35,121 (146.8%)   Cash flow hedges, net of income tax(776)- (100.0%)  Remeasurements of employee benefit – net income tax32,099 18,642 (41.9%)  Comprehensive income 2,814,380 3,365,771 19.6%  Non-controlling interest(114,926)(138,515)20.5%  Comprehensive income attributable to controlling interest2,699,454 3,227,255 19.6%        The non-controlling interest corresponds to the 25.5% stake held in the Montego Bay airport by Vantage Airport Group Limited (“Vantage”), as well as the 48.5% held by the shareholders of GWTC.

Exhibit E: Consolidated stockholders’ equity (in thousands of pesos): 

  Common StockLegal ReserveReserve for Share RepurchaseRetained EarningsOther comprehensive incomeTotal controlling interestNon-controlling interestTotal Stockholders' Equity Balance as of January 1, 20251,194,390920,1872,500,00016,957,723773,499 22,345,799 2,275,94024,621,739  Comprehensive income:         Net income---2,748,127- 2,748,127 109,9962,858,123  Foreign currency translation reserve----(79,988)(79,988)4,930(75,058) Remeasurements of employee benefit – Net----32,099 32,099 -32,099  Reserve for cash flow hedges – Net of income tax----(776)(776)-(776) Balance as of March 31, 20251,194,390920,1872,500,00019,705,850724,834 25,045,258 2,390,86627,436,125            Balance as of January 1, 20261,194,390238,8782,500,00018,695,331(158,148)22,470,451 2,365,48024,835,931  Comprehensive income:         Net income---3,178,332- 3,178,332 133,6853,312,017  Foreign currency translation reserve----30,291 30,291 4,83035,121  Remeasurements of employee benefit – Net----18,642 18,642 -18,642  Balance as of March 31, 20261,194,390238,8782,500,00021,873,663(109,215)25,697,716 2,503,99528,201,711            The non-controlling interest corresponds to the 25.5% stake held in the Montego Bay airport by Vantage Airport Group Limited (“Vantage”), as well as the 48.5% held by the shareholders of GWTC.

Exhibit F: Other operating data: 

Other data (thousands)    1Q251Q26ChangeTotal passengers16,269.615,367.2(5.5%)Total cargo volume (in WLUs)650.7703.88.2%Total WLUs16,920.216,071.0(5.0%)    Aeronautical & non aeronautical services per passenger (pesos)515.9571.010.7%Aeronautical services per WLU (pesos)354.6387.99.4%Non aeronautical services per passenger (pesos)147.1165.312.3%Cost of services per WLU (pesos)87.896.510.0%     WLU = Workload units represent passenger traffic plus cargo units (1 cargo unit = 100 kilograms of cargo).

Alejandra Soto Investor Relations and Social Responsibility Officer
[email protected]

Gisela Murillo, Investor Relations
[email protected]
+52 33 3880 1100 ext. 20294

GUADALAJARA, Mexico, April 23, 2026 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces the following resolutions adopted at the Annual General Ordinary Shareholders’ Meetings held yesterday, with a quorum of 84.01%:

I. In compliance with Article 28 section IV of the Securities Market Law, the following were approved: a) The Chief Executive Officer’s report regarding the results of operations for the fiscal year ended December 31, 2025, in accordance with Article 44, Section XI of the Mexican Securities Market Law and Article 172 of the Mexican General Corporations Law, together with the external auditor’s report, with respect to the Company on an unconsolidated basis in accordance with Mexican Financial Reporting Standards (“MFRS”), as well as with respect to the Company and its subsidiaries on a consolidated basis in accordance with International Financial Reporting Standards (“IFRS”), based on the latest statements of financial position for fiscal year 2025 under both standards, as well as the Sustainability Report for fiscal year 2025. b)Board of directors’ opinion on the Chief Executive Officer’s report. c)Board of directors’ report in accordance with Article 172, clause b, of the Mexican General Corporations Law, regarding the Company’s main accounting policies and criteria, as well as the information used to prepare the Company’s financial statements. d)Report on transactions and activities undertaken by the Company’s Board of Directors during the fiscal year ended December 31, 2025, pursuant to the Mexican Securities Market Law.    e)Report on the activities carried out by the Audit and Corporate Practices Committee in accordance with Article 43 of the Securities Market Law. Ratification of the actions taken by the different committees and release from further obligations in the fulfillment of their duties. f)Report on compliance with the Company’s tax obligations for the fiscal year from January 1 to December 31, 2024. Instruction to the Company’s officers to comply with the corresponding tax obligations for the fiscal year from January 1 to December 31, 2025, in accordance with Article 26 section III of the Mexican Fiscal Code.   II. Ratification of the actions of our Board of Directors and the Company’s management and release from further obligations in the fulfillment of their duties.   III. Approval of the Company’s non-consolidated financial statements for the period from January 1 to December 31, 2025, prepared under MFRS for purposes of the legal reserve, profit allocation, calculation of tax effects of dividend payments and capital reductions, if applicable. Also, the consolidated financial statements of the Company and its subsidiaries prepared under IFRS for publication in the securities markets, regarding the operations carried out during the fiscal year from January 1 to December 31, 2025, and approval of the external auditor’s opinion with respect to both financial statements.   IV.  Approval that the net income obtained by the Company during the fiscal year ended December 31, 2025, reported in the Company’s non-consolidated financial statements presented to the meeting under Item III above and audited under MFRS, amounting to $9,343,142,610.00 (NINE BILLION THREE HUNDRED FORTY-THREE MILLION ONE HUNDRED FORTY-TWO THOUSAND SIX HUNDRED TEN PESOS 00/100 M.N.), be fully transferred to the account of retained earnings pending allocation, without setting aside any amount for the legal reserve fund, since the current fund represents 20% of the historical capital stock required by Article 20 of the Mexican General Corporations Law.   V. Approval that from the retained earnings pending allocation account, which amounts to $20,379,864,675.00 (TWENTY BILLION THREE HUNDRED SEVENTY-NINE MILLION EIGHT HUNDRED SIXTY-FOUR THOUSAND SIX HUNDRED SEVENTY-FIVE PESOS 00/100 M.N.), a dividend of $20.80 (TWENTY PESOS 80/100 M.N.) per share be declared, payable to the holders of each of the shares outstanding on the payment date, excluding the shares repurchased by the Company in accordance with Article 56 of the Securities Market Law. The remaining balance, after the dividend payment, will remain in the retained earnings pending allocation account. The dividend will be payable in one or more installments within the 12 (twelve) months following April 22, 2026.   VI. Approval of the cancellation of any amount outstanding under the share repurchase program approved at the Annual General Ordinary Shareholders’ Meeting held on April 24, 2025, in the amount of $2,500,000,000.00 (TWO BILLION FIVE HUNDRED MILLION PESOS 00/100 M.N.). Also, approval of the maximum amount to be allocated for the repurchase of the Company’s own shares or securities representing such shares for an amount of $2,500,000,000.00 (TWO BILLION FIVE HUNDRED MILLION PESOS 00/100 M.N.), for the period of 12 (twelve) months following April 22, 2026, in accordance with Article 56 section IV of the Securities Market Law.   VII. Acknowledge of the designation of the four principal members of the Board of Directors and their respective alternates appointed by the Series “BB” shareholders as follows:     Proprietary members                                     Alternate members
Laura Díez Barroso Azcárraga                        Claudia Laviada Díez Barroso
Emilio Rotondo Inclán                                      Roberto Ángel Ramírez García
Juan Gallardo Thurlow                                     Mónica Sánchez Navarro Rivera Torres
María de los Reyes Escrig Teigeiro                 Carlos Alberto Rohm CamposVIII.  It is registered that there was no designation of person(s) that will serve as member(s) of the Company’s Board of Directors, by any holder or group of holders of Series B shares that owns, individually or collectively, 10% or more of the Company’s capital stock.    IX. Ratification and designation of Carlos Cárdenas Guzmán, Ángel Losada Moreno, Joaquín Vargas Guajardo, Juan Diez-Canedo Ruíz, Luis Téllez Kuenzler, Jerónimo Marcos Gerard Rivero and Alejandra Yazmín Soto Ayech, as members of the Board of Directors, designated by the Series “B” shareholders. As of this date, the Board of Directors will be comprised as follows:

Proprietary members                                    Alternate members
Laura Díez Barroso Azcárraga                       Claudia Laviada Díez Barroso
Emilio Rotondo Inclán                                     Roberto Ángel Ramírez García
Juan Gallardo Thurlow                                    Mónica Sánchez Navarro Rivera Torres
María de los Reyes Escrig Teigeiro                Carlos Alberto Rohm Campos
Carlos Cárdenas Guzmán                              Not applicable
Ángel Losada Moreno                                     Not applicable
Joaquín Vargas Guajardo                               Not applicable
Juan Diez-Canedo Ruíz                                  Not applicable
Luis Téllez Kuenzler                                        Not applicable
Jerónimo Marcos Gerard Rivero                     Not applicable
Alejandra Yazmín Soto Ayech                         Not applicable

   X. Ratification of Mrs. Laura Díez Barros Azcárraga as Chairwoman of Company’s the Board of Directors, in accordance with Article Sixteenth of the Company’s bylaws.   XI. Approval of the compensation paid to members of the Company’s Board of Directors during fiscal year 2025 and the compensation to be paid to the Company’s Board of Directors for the 2026 fiscal year proposed by the Compensation and Nominations Committee.   XII. Ratification of Mr. Luis Téllez Kuenzler, as member of our Board of Directors designated by the Series “B” shareholders to serve as member of the Nominations and Compensation Committee, in accordance with Article Twenty-Eighth of the Company’s bylaws.   XIII. Ratification of Mr. Carlos Cárdenas Guzmán as President of the Audit and Corporate Practices Committee.   XIV.  It was informed the Report in accordance with Article Twenty-Ninth of the Company’s bylaws regarding transactions involving the acquisition of goods or services, contracting of works, or sale of assets equal to or greater than US$3,000,000 (THREE MILLION U.S. DOLLARS) or its equivalent in Mexican pesos or other currencies, or transactions carried out by relevant shareholders, if any.       XV. Approval of special delegates that can appear before a Notary Public to formalize the resolutions adopted at this meeting.
Company Description

Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (GAP) operates 12 airports throughout Mexico’s Pacific region, including the major cities of Guadalajara and Tijuana, the four tourist destinations of Puerto Vallarta, Los Cabos, La Paz and Manzanillo, and six other mid-sized cities: Hermosillo, Guanajuato, Morelia, Aguascalientes, Mexicali, and Los Mochis. In February 2006, GAP’s shares were listed on the New York Stock Exchange under the ticker symbol “PAC” and on the Mexican Stock Exchange under the ticker symbol “GAP”. In April 2015, GAP acquired 100% of Desarrollo de Concessioner Aeroportuarias, S.L., which owns a majority stake in MBJ Airports Limited, a company operating Sangster International Airport in Montego Bay, Jamaica. In October 2018, GAP entered into a concession agreement for the Norman Manley International Airport operation in Kingston, Jamaica, and took control of the operation in October 2019.

This press release may contain forward-looking statements. These statements are statements that are not historical facts and are based on management’s current view and estimates of future economic circumstances, industry conditions, company performance, and financial results. The words “anticipates”, “believes”, “estimates”, “expects”, “plans” and similar expressions, as they relate to the company, are intended to identify forward-looking statements. Statements regarding the declaration or payment of dividends, the implementation of principal operating and financing strategies and capital expenditure plans, the direction of future operations, and the factors or trends affecting financial condition, liquidity, or results of operations are examples of forward-looking statements. Such statements reflect the current views of management and are subject to a number of risks and uncertainties. There is no guarantee that the expected events, trends, or results will occur. The statements are based on many assumptions and factors, including general economic and market conditions, industry conditions, and operating factors. Any changes in such assumptions or factors could cause actual results to differ materially from current expectations.

In accordance with Section 806 of the Sarbanes-Oxley Act of 2002 and Article 42 of the “Ley del Mercado de Valores”, GAP has implemented a “whistleblower” program, which allows complainants to anonymously and confidentially report suspected activities that involve criminal conduct or violations. The telephone number in Mexico, facilitated by a third party responsible for collecting these complaints, is 800 04 ETICA (38422) or WhatsApp +52 55 6538 5504. The website is www.lineadedenunciagap.com or by email at [email protected]. GAP’s Audit Committee will be notified of all complaints for immediate investigation.

Alejandra Soto Investor Relations and Social Responsibility OfficerGisela Murillo, Investor Relations

[email protected]@aeropuertosgap.com.mx
+52 33 3880 1100 ext. 20294

GUADALAJARA, Mexico, May 04, 2026 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) reports that, following the announcement made by Spirit Airlines on May 2 regarding the immediate cessation of its operations, the Company has conducted an assessment of the potential impact on its airports.

Spirit Airlines did not operate at any of the Mexican airports managed by GAP. In Jamaica, its participation represented a limited portion of total passenger traffic, accounting for approximately 3.5% of passenger traffic in Kingston and 2.6% in Montego Bay.

Spirit’s operations at both airports were concentrated on routes to Florida, specifically Fort Lauderdale, Miami, and Orlando, markets that currently have available capacity served by other airlines, including JetBlue, American Airlines, and Southwest Airlines.

GAP does not maintain any material exposure arising from accounts receivable with Spirit Airlines. As of this date, the outstanding balances owed by the airline are fully covered by bank guarantees and cash deposits; therefore, there will be no financial impact.

GAP will continue to closely monitor developments in the Jamaican air travel market and will remain in communication with authorities and airlines to facilitate the reallocation of capacity on the affected routes, with the objective of preserving connectivity and minimizing any operational impact.

Company Description

Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (GAP) operates 12 airports throughout Mexico’s Pacific region, including the major cities of Guadalajara and Tijuana, the four tourist destinations of Puerto Vallarta, Los Cabos, La Paz and Manzanillo, and six other mid-sized cities: Hermosillo, Guanajuato, Morelia, Aguascalientes, Mexicali, and Los Mochis. In February 2006, GAP’s shares were listed on the New York Stock Exchange under the ticker symbol “PAC” and on the Mexican Stock Exchange under the ticker symbol “GAP”. In April 2015, GAP acquired 100% of Desarrollo de Concessioner Aeroportuarias, S.L., which owns a majority stake in MBJ Airports Limited, a company operating Sangster International Airport in Montego Bay, Jamaica. In October 2018, GAP entered into a concession agreement for the Norman Manley International Airport operation in Kingston, Jamaica, and took control of the operation in October 2019.

This press release may contain forward-looking statements. These statements are statements that are not historical facts and are based on management’s current view and estimates of future economic circumstances, industry conditions, company performance, and financial results. The words “anticipates”, “believes”, “estimates”, “expects”, “plans” and similar expressions, as they relate to the company, are intended to identify forward-looking statements. Statements regarding the declaration or payment of dividends, the implementation of principal operating and financing strategies and capital expenditure plans, the direction of future operations, and the factors or trends affecting financial condition, liquidity, or results of operations are examples of forward-looking statements. Such statements reflect the current views of management and are subject to a number of risks and uncertainties. There is no guarantee that the expected events, trends, or results will occur. The statements are based on many assumptions and factors, including general economic and market conditions, industry conditions, and operating factors. Any changes in such assumptions or factors could cause actual results to differ materially from current expectations.

In accordance with Section 806 of the Sarbanes-Oxley Act of 2002 and Article 42 of the “Ley del Mercado de Valores”, GAP has implemented a “whistleblower” program, which allows complainants to anonymously and confidentially report suspected activities that involve criminal conduct or violations. The telephone number in Mexico, facilitated by a third party responsible for collecting these complaints, is 800 04 ETICA (38422) or WhatsApp +52 55 6538 5504. The website is www.lineadedenunciagap.com or by email at [email protected]. GAP’s Audit Committee will be notified of all complaints for immediate investigation.

Alejandra Soto Investor Relations and Social Responsibility [email protected]  Gisela Murillo, Investor [email protected]
+52 33 3880 1100 ext. 20294

GUADALAJARA, Mexico, May 05, 2026 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces preliminary terminal passenger traffic figures for April 2026, compared with April 2025.

During April 2026, the 12 Mexican airports operated by GAP recorded a 6.3% decrease in total passenger traffic compared to April 2025. Guadalajara airport reported an increase of 0.9%, while Puerto Vallarta, Tijuana and Los Cabos reported a decrease of 17.0%, 10.5%, and 8.1%, respectively, compared to April 2025. With respect to GAP’s airports in Jamaica, Kingston recorded a decrease of 6.0%, while Montego Bay recorded a decrease of 22.0%, as a result of disruptions caused by Hurricane Melissa.

Domestic Terminal Passengers (in thousands):

AirportApr-25Apr-26% ChangeJan - Apr 25Jan - Apr 26% ChangeGuadalajara1,067.51,066.2(0.1%)4,088.64,101.80.3% Tijuana*748.6671.7(10.3%)2,806.12,640.2(5.9%)Los Cabos254.6240.9(5.4%)923.5869.2(5.9%)Puerto Vallarta278.4255.1(8.4%)932.0899.9(3.4%)Montego Bay0.00.0N/A0.00.0N/AGuanajuato194.0179.1(7.7%)709.6689.9(2.8%)Hermosillo184.4166.0(10.0%)693.1646.6(6.7%)Kingston0.00.0(28.0%)0.10.7610.9% Morelia60.258.3(3.2%)246.3251.22.0% La Paz111.8123.210.2% 392.4437.011.4% Mexicali105.090.5(13.8%)398.2350.2(12.0%)Aguascalientes53.355.13.5% 205.1194.0(5.4%)Los Mochis66.560.8(8.6%)231.6224.1(3.2%)Manzanillo10.79.9(7.4%)45.542.8(6.0%)Total3,135.22,976.9(5.0%)11,672.011,347.7(2.8%)  International Terminal Passengers (in thousands):

AirportApr-25Apr-26% ChangeJan - Apr 25Jan - Apr 26% ChangeGuadalajara452.9467.23.2% 1,959.91,959.3(0.0%)Tijuana*351.1312.8(10.9%)1,366.01,210.4(11.4%)Los Cabos442.9400.1(9.7%)1,825.81,772.8(2.9%)Puerto Vallarta375.7287.5(23.5%)1,848.21,566.4(15.2%)Montego Bay430.4335.6(22.0%)1,769.41,252.9(29.2%)Guanajuato84.372.2(14.3%)347.4330.1(5.0%)Hermosillo6.16.914.2% 27.028.97.0% Kingston155.0145.7(6.0%)583.0560.5(3.9%)Morelia56.064.915.9% 230.2280.722.0% La Paz3.04.655.2% 11.717.247.2% Mexicali0.60.6(8.9%)2.42.40.6% Aguascalientes27.529.57.5% 101.1106.85.6% Los Mochis0.70.711.5% 2.62.60.7% Manzanillo9.88.2(15.9%)53.744.5(17.0%)Total2,395.82,136.5(10.8%)10,128.39,135.5(9.8%)  Total Terminal Passengers (in thousands):

AirportApr-25Apr-26% ChangeJan - Apr 25Jan - Apr 26% ChangeGuadalajara1,520.41,533.40.9% 6,048.56,061.10.2% Tijuana*1,099.7984.5(10.5%)4,172.03,850.6(7.7%)Los Cabos697.5641.0(8.1%)2,749.32,642.0(3.9%)Puerto Vallarta654.1542.6(17.0%)2,780.22,466.3(11.3%)Montego Bay430.4335.6(22.0%)1,769.41,252.9(29.2%)Guanajuato278.4251.3(9.7%)1,057.01,020.0(3.5%)Hermosillo190.5173.0(9.2%)720.1675.5(6.2%)Kingston155.0145.7(6.0%)583.1561.2(3.8%)Morelia116.2123.26.0% 476.5532.011.6% La Paz114.8127.811.4% 404.1454.212.4% Mexicali105.691.0(13.8%)400.5352.6(12.0%)Aguascalientes80.784.74.9% 306.2300.8(1.8%)Los Mochis67.261.5(8.4%)234.1226.6(3.2%)Manzanillo20.518.1(11.4%)99.287.3(12.0%)Total5,531.05,113.4(7.6%)21,800.320,483.2(6.0%)       *Passengers in Tijuana who use CBX in both directions are classified as international.  CBX users (in thousands):

AirportApr-25Apr-26% ChangeJan - Apr 25Jan - Apr 26% ChangeTijuana345.0309.4(10.3%)
1,343.21,195.7(11.0%)
  Highlights for the month:

Seats and load factors
The seats available during April 2026 decreased by 8.3%, compared to April 2025. The load factors for the month went from 80.8% in April 2025 to 81.5% in April 2026.

Company Description

Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (GAP) operates 12 airports throughout Mexico’s Pacific region, including the major cities of Guadalajara and Tijuana, the four tourist destinations of Puerto Vallarta, Los Cabos, La Paz and Manzanillo, and six other mid-sized cities: Hermosillo, Guanajuato, Morelia, Aguascalientes, Mexicali, and Los Mochis. In February 2006, GAP’s shares were listed on the New York Stock Exchange under the ticker symbol “PAC” and on the Mexican Stock Exchange under the ticker symbol “GAP”. In April 2015, GAP acquired 100% of Desarrollo de Concessioner Aeroportuarias, S.L., which owns a majority stake in MBJ Airports Limited, a company operating Sangster International Airport in Montego Bay, Jamaica. In October 2018, GAP entered into a concession agreement for the Norman Manley International Airport operation in Kingston, Jamaica, and took control of the operation in October 2019.

 This press release may contain forward-looking statements. These statements are statements that are not historical facts and are based on management’s current view and estimates of future economic circumstances, industry conditions, company performance, and financial results. The words “anticipates”, “believes”, “estimates”, “expects”, “plans” and similar expressions, as they relate to the company, are intended to identify forward-looking statements. Statements regarding the declaration or payment of dividends, the implementation of principal operating and financing strategies and capital expenditure plans, the direction of future operations, and the factors or trends affecting financial condition, liquidity, or results of operations are examples of forward-looking statements. Such statements reflect the current views of management and are subject to a number of risks and uncertainties. There is no guarantee that the expected events, trends, or results will occur. The statements are based on many assumptions and factors, including general economic and market conditions, industry conditions, and operating factors. Any changes in such assumptions or factors could cause actual results to differ materially from current expectations.     In accordance with Section 806 of the Sarbanes-Oxley Act of 2002 and Article 42 of the “Ley del Mercado de Valores”, GAP has implemented a “whistleblower” program, which allows complainants to anonymously and confidentially report suspected activities that involve criminal conduct or violations. The telephone number in Mexico, facilitated by a third party responsible for collecting these complaints, is 800 04 ETICA (38422) or WhatsApp +52 55 6538 5504. The website is www.lineadedenunciagap.com or by email at [email protected]. GAP’s Audit Committee will be notified of all complaints for immediate investigation.

GUADALAJARA, Mexico, May 09, 2026 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (NYSE: PAC; BMV: GAP) (the “Company” or “GAP”) announces that it has initiated the process for the potential establishment of an Irrevocable Trust for the Issuance of Energy and Infrastructure Investment Trust Certificates (“FIBRA GAP”), with the objective of subscribing a minority equity interest in the 12 Mexican airport concessionaires operated by GAP.

Through the initial issuance of FIBRA GAP, each of the 12 airports intends to obtain funds to complement the execution of the Master Development Program for the 2026–2029 period, which contemplates investments of approximately Ps. 40.0 billion.

The Master Development Program will generate significant growth in airport infrastructure, including an approximate increase of 60% in terminals, 35% in inspection points and access areas, 25% in aircraft parking positions, and 10% in airside infrastructure.

These investments will contribute to economic development in the areas surrounding the airports through the generation of direct and indirect employment, as well as a multiplier effect on investment.

The investment made by FIBRA GAP in the airports will represent an additional source of funds to invest in airport infrastructure, complementing the debt securities issuances under the program that GAP has utilized since 2015.

Company Description

Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (GAP) operates 12 airports throughout Mexico’s Pacific region, including the major cities of Guadalajara and Tijuana, the four tourist destinations of Puerto Vallarta, Los Cabos, La Paz and Manzanillo, and six other mid-sized cities: Hermosillo, Guanajuato, Morelia, Aguascalientes, Mexicali, and Los Mochis. In February 2006, GAP’s shares were listed on the New York Stock Exchange under the ticker symbol “PAC” and on the Mexican Stock Exchange under the ticker symbol “GAP”. In April 2015, GAP acquired 100% of Desarrollo de Concessioner Aeroportuarias, S.L., which owns a majority stake in MBJ Airports Limited, a company operating Sangster International Airport in Montego Bay, Jamaica. In October 2018, GAP entered into a concession agreement for the Norman Manley International Airport operation in Kingston, Jamaica, and took control of the operation in October 2019.

This press release may contain forward-looking statements. These statements are statements that are not historical facts and are based on management’s current view and estimates of future economic circumstances, industry conditions, company performance, and financial results. The words “anticipates”, “believes”, “estimates”, “expects”, “plans” and similar expressions, as they relate to the company, are intended to identify forward-looking statements. Statements regarding the declaration or payment of dividends, the implementation of principal operating and financing strategies and capital expenditure plans, the direction of future operations, and the factors or trends affecting financial condition, liquidity, or results of operations are examples of forward-looking statements. Such statements reflect the current views of management and are subject to a number of risks and uncertainties. There is no guarantee that the expected events, trends, or results will occur. The statements are based on many assumptions and factors, including general economic and market conditions, industry conditions, and operating factors. Any changes in such assumptions or factors could cause actual results to differ materially from current expectations.  In accordance with Section 806 of the Sarbanes-Oxley Act of 2002 and Article 42 of the “Ley del Mercado de Valores”, GAP has implemented a “whistleblower” program, which allows complainants to anonymously and confidentially report suspected activities that involve criminal conduct or violations. The telephone number in Mexico, facilitated by a third party responsible for collecting these complaints, is 800 04 ETICA (38422) or WhatsApp +52 55 6538 5504. The website is www.lineadedenunciagap.com or by email at [email protected]. GAP’s Audit Committee will be notified of all complaints for immediate investigation.

Alejandra Soto Investor Relations and Social Responsibility [email protected]  Gisela Murillo, Investor [email protected]
+52 33 3880 1100 ext. 20294

More than one-third of responders with previously treated disease achieved complete responses, with median duration of response not yet reached, as reported in new Journal of Clinical Oncology publication RYBREVANT FASPRO™, an EGFR- and MET-targeting dual inhibitor, is the first and only subcutaneous therapy being evaluated in this setting Johnson & Johnson submitted a supplemental Biologics License Application to U.S. FDA seeking approval for this indication , /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced pivotal results from the Phase 1b/2 OrigAMI-4 study showing that subcutaneous amivantamab and hyaluronidase-lpuj delivered durable responses in patients with advanced head and neck squamous cell carcinoma previously treated with immunotherapy and chemotherapy. Confirmed overall response rate was 42 percent, with more than one-third of responders achieving complete responses. Median duration of response was not yet reached, with a median follow up of 11.8 months.1 These data were featured in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #6008) and simultaneously published in the Journal of Clinical Oncology (JCO).2 Together, with additional data presented in lung and colorectal cancers, these findings further demonstrate the expanding role of the amivantamab portfolio across tumor types.

A supplemental Biologics License Application (sBLA) seeking approval for subcutaneous amivantamab in head and neck cancer has been submitted to the U.S. Food and Drug Administration (FDA), following Breakthrough Therapy Designation.

High unmet need remains in advanced head and neck cancer

Head and neck squamous cell carcinoma is an aggressive disease that can significantly affect quality of life, with symptoms such as pain and difficulty swallowing that can make it hard to eat, speak and maintain proper nutrition.3,4 Certain forms of head and neck cancer, including tumors of the mouth, voice box and parts of the throat, are among the most difficult to treat, and are associated with poorer outcomes and persistent unmet need.5 Across head and neck cancers, up to half of patients will experience recurrence or metastatic disease, even when treated at an early stage.3 Once the disease becomes recurrent or metastatic, five-year survival is approximately 15 percent.6 For patients who receive additional treatment, current options provide limited benefit with response rates rarely exceeding 24 percent, and few patients achieve a complete response.7,8

Dual-targeting mechanism helps address tumor growth and resistance

Subcutaneous amivantamab is designed to dual target both epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET), two pathways associated with tumor growth and resistance, while engaging the immune system.9

"Patients with recurrent or metastatic head and neck cancer who have already been treated with immunotherapy and chemotherapy face very poor outcomes," said Barbara Burtness, M.D.,* medical oncologist and professor of medicine at Yale Cancer Center in New Haven, Connecticut. "The high response seen with subcutaneous amivantamab on its own, including more than one-third of responders achieving complete responses, and the durability of those responses, suggests it has the potential to meaningfully improve expectations for these patients."

Detailed OrigAMI-4 study results

Cohort 1 of the OrigAMI-4 study evaluated subcutaneous amivantamab monotherapy in 102 patients with recurrent or metastatic head and neck cancer who had previously received immunotherapy and platinum-based chemotherapy, excluding patients with human papillomavirus (HPV)-positive oropharyngeal cancer. Patients received treatment every three weeks following an initial loading dose. The primary endpoint was overall response rate, as assessed by local investigators per protocol. Responses were confirmed via blinded independent central review (BICR).1

Based on BICR, confirmed overall response rate was 42 percent (95 percent confidence interval [CI], 32-52), including complete responses in more than one-third of responders (15 percent) and a 27 percent partial response rate. Clinical benefit rate was 63 percent (95 percent CI, 53-72), and median time to first response was 6.6 weeks (range, 5.6-36.9). At the time of analysis (median follow-up of 11.8 months), median duration of response had not yet been reached among confirmed responders, demonstrating notable durability. Median progression-free survival and overall survival were 6.8 months and 12.5 months, respectively.1

The safety profile of subcutaneous amivantamab monotherapy was consistent with prior reports, with no new safety signals identified. Most treatment-related adverse events were Grade 1 or 2 (mild to moderate) and associated with EGFR or MET inhibition. The most common on-target adverse events included hypoalbuminemia (50 percent), rash (37 percent), paronychia (34 percent) and dermatitis acneiform (34 percent). Administration-related reactions occurred in 15 percent of patients, with no Grade 3 or higher events reported. Treatment-related discontinuations remained low at eight percent.1

"Progress has been limited for patients with recurrent and metastatic head and neck cancer, highlighting the need for differentiated approaches that can address the disease more comprehensively," said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson. "Subcutaneous amivantamab is the only therapy of its kind being studied in this disease, targeting both EGFR and MET while engaging the immune system. The encouraging responses we're seeing in OrigAMI-4, along with a well-established and manageable safety profile, underscore the potential of this approach and move us closer to delivering a fast, convenient treatment option."

Ongoing study of RYBREVANT FASPRO™ in head and neck cancer

A trial-in-progress update from the Phase 3 OrigAMI-5 study (NCT07276399) was also shared at ASCO 2026 (Abstract #583a). The study is evaluating subcutaneous amivantamab in combination with carboplatin and pembrolizumab as a first-line treatment for patients with recurrent or metastatic head and neck cancer, with the goal of improving outcomes in the first-line setting.10

RYBREVANT FASPRO™ is already approved in more than 40 countries, including the United States, Europe, Japan, and other markets, as a subcutaneous treatment for patients with EGFR-mutated non-small cell lung cancer.11

About the OrigAMI-4 Study

OrigAMI-4 (NCT06385080) is an open-label Phase 1b/2 study evaluating RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). The study includes five cohorts exploring RYBREVANT FASPRO™ across different treatment settings and regimens.

Cohort 1 evaluated RYBREVANT FASPRO™ as monotherapy in patients with R/M HNSCC who had received prior platinum-based chemotherapy and PD-1/PD-L1 immunotherapy. Patients with HPV-positive oropharyngeal squamous cell carcinoma were excluded, as well as those with prior anti-EGFR therapy.

RYBREVANT FASPRO™ was administered on a weekly schedule during the initial treatment period followed by dosing every three weeks (Q3W), with weight-based dosing adjustments. The primary endpoint across cohorts is overall response rate (ORR), as assessed by investigators, using RECIST v1.1.†12

About Head and Neck Squamous Cell Carcinoma

Head and neck squamous cell carcinoma (HNSCC) is the most common form of head and neck cancer, a group of cancers that arise in the mouth, throat, voice box, sinuses, nasal cavity, and salivary glands.13 It represents approximately 4.5 percent of all cancers worldwide and is the seventh most common cancer globally.13 Major risk factors include tobacco and alcohol use, as well as infection with high-risk human papillomavirus (HPV).13 Approximately 80 percent of recurrent or metastatic HNSCC are not driven by HPV, and are typically associated with poorer prognosis and reduced response to treatment.13, 14 Despite advances in surgery, radiation, chemotherapy, and immunotherapy, many patients ultimately progress to advanced, recurrent or metastatic disease.15,16

About RYBREVANT FASPRO™ and RYBREVANT®

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) received U.S. FDA approval in December 2025 and is approved in multiple markets worldwide for the treatment of adults with EGFR-mutated non-small cell lung cancer (NSCLC), including those with exon 19 deletions, exon 21 L858R substitution mutations, and exon 20 insertion mutations. It is the only subcutaneous therapy approved in these populations and can be used as monotherapy or in combination with LAZCLUZE® (lazertinib) or chemotherapy in the front- and second-line settings, offering convenient monthly‡ or bi-weekly dosing. RYBREVANT FASPRO™ is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE® drug delivery technology.

RYBREVANT® (amivantamab-vmjw), administered intravenously, received U.S. FDA approval in March 2024 and is approved for the same indications as RYBREVANT FASPRO™ across multiple markets. RYBREVANT® is a first-in-class, fully human bispecific antibody targeting EGFR and MET, designed to inhibit tumor growth while engaging the immune system.

The effectiveness of RYBREVANT FASPRO™ is supported by the established clinical profile of RYBREVANT®, including data from multiple Phase 3 studies such as MARIPOSA, which demonstrated improvements in progression-free and overall survival when used in combination with LAZCLUZE® in first-line advanced EGFR-mutated NSCLC.

The National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®)§17 include amivantamab-vmjw (RYBREVANT®) across its FDA-approved treatment settings, including as a Category 1 preferred option in combination with lazertinib (LAZCLUZE®) for first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations. Subcutaneous amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO™) may be substituted for IV amivantamab-vmjw (RYBREVANT®) where appropriate. See the latest NCCN Guidelines® for NSCLC for complete information. || ¶

The NCCN Guidelines for Central Nervous System Cancers also include amivantamab (RYBREVANT®)-based regimens, including in combination with lazertinib (LAZCLUZE®), as the only NCCN-preferred combination options for patients with EGFR-mutated NSCLC and brain metastases. || ¶

Beyond NSCLC, RYBREVANT-based therapies are being investigated across other solid tumors, including head and neck and colorectal cancers.

The legal manufacturer for RYBREVANT FASPRO™ and RYBREVANT® is Janssen Biotech, Inc. For more information, visit www.rybrevanthcp.com

INDICATIONS

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) and RYBREVANT® (amivantamab-vmjw) are indicated:

in combination with LAZCLUZE (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test.as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA approved test, whose disease has progressed on or after platinum-based chemotherapy.IMPORTANT SAFETY INFORMATION FOR RYBREVANT FASPRO™ AND RYBREVANT® 10,18

CONTRAINDICATIONS

RYBREVANT FASPRO™ is contraindicated in patients with known hypersensitivity to hyaluronidase or to any of its excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity and Administration-Related Reactions with RYBREVANT FASPRO™

RYBREVANT FASPRO™ can cause hypersensitivity and administration-related reactions (ARR); signs and symptoms of ARR include dyspnea, flushing, fever, chills, chest discomfort, hypotension, and vomiting. The median time to ARR onset is approximately 2 hours.

RYBREVANT FASPRO™ with LAZCLUZE®

In PALOMA-3 (n=206), all Grade ARR occurred in 13% of patients, including 0.5% Grade 3. Of the patients who experienced ARR, 89% occurred with the initial dose (Week 1, Day 1).

Premedicate with antihistamines, antipyretics, and glucocorticoids and administer RYBREVANT FASPRO™ as recommended. Monitor patients for any signs and symptoms of administration-related reactions during injection in a setting where cardiopulmonary resuscitation medication and equipment are available. Interrupt RYBREVANT FASPRO™ injection if ARR is suspected. Resume treatment upon resolution of symptoms or permanently discontinue RYBREVANT FASPRO™ based on severity.

Infusion-Related Reactions with RYBREVANT®

RYBREVANT® can cause infusion-related reactions (IRR) including anaphylaxis; signs and symptoms of IRR include dyspnea, flushing, fever, chills, nausea, chest discomfort, hypotension, and vomiting. The median time to IRR onset is approximately 1 hour.

RYBREVANT® with LAZCLUZE®

In MARIPOSA (n=421), IRRs occurred in 63% of patients, including Grade 3 in 5% and Grade 4 in 1% of patients. IRR-related infusion modifications occurred in 54%, dose reduction in 0.7%, and permanent discontinuation of RYBREVANT® in 4.5% of patients.

RYBREVANT® with Carboplatin and Pemetrexed

Based on the pooled safety population (n=281), IRRs occurred in 50% of patients including Grade 3 (3.2%) adverse reactions. IRR-related infusion modifications occurred in 46%, and permanent discontinuation of RYBREVANT® in 2.8% of patients.

RYBREVANT® as a Single Agent

In CHRYSALIS (n=302), IRRs occurred in 66% of patients. IRRs occurred in 65% of patients on Week 1 Day 1, 3.4% on Day 2 infusion, 0.4% with Week 2 infusion, and were cumulatively 1.1% with subsequent infusions. 97% were Grade 1-2, 2.2% were Grade 3, and 0.4% were Grade 4. The median time to onset was 1 hour (range: 0.1 to 18 hours) after start of infusion. IRR-related infusion modifications occurred in 62%, and permanent discontinuation of RYBREVANT® in 1.3% of patients.

Premedicate with antihistamines, antipyretics, and glucocorticoids and infuse RYBREVANT® as recommended. Administer RYBREVANT® via a peripheral line on Week 1 and Week 2 to reduce the risk of IRRs. Monitor patients for signs and symptoms of IRRs in a setting where cardiopulmonary resuscitation medication and equipment are available. Interrupt infusion if IRR is suspected. Reduce the infusion rate or permanently discontinue RYBREVANT® based on severity. If an anaphylactic reaction occurs, permanently discontinue RYBREVANT®.

Interstitial Lung Disease/Pneumonitis

RYBREVANT FASPRO™ and RYBREVANT® can cause severe and fatal interstitial lung disease (ILD)/pneumonitis.

RYBREVANT FASPRO™ with LAZCLUZE®

In PALOMA-3, ILD/pneumonitis occurred in 6% of patients, including Grade 3 in 1%, Grade 4 in 1.5%, and fatal cases in 1.9% of patients. 5% of patients permanently discontinued RYBREVANT FASPRO™ and LAZCLUZE® due to ILD/pneumonitis.

RYBREVANT® with LAZCLUZE®

In MARIPOSA, ILD/pneumonitis occurred in 3.1% of patients, including Grade 3 in 1.0% and Grade 4 in 0.2% of patients. There was one fatal case of ILD/pneumonitis and 2.9% of patients permanently discontinued RYBREVANT® and LAZCLUZE® due to ILD/pneumonitis.

RYBREVANT® with Carboplatin and Pemetrexed

Based on the pooled safety population, ILD/pneumonitis occurred in 2.1% of patients with 1.8% of patients experiencing Grade 3 ILD/pneumonitis. 2.1% discontinued RYBREVANT® due to ILD/pneumonitis.

RYBREVANT® as a Single Agent

In CHRYSALIS, ILD/pneumonitis occurred in 3.3% of patients, with 0.7% of patients experiencing Grade 3 ILD/pneumonitis. Three patients (1%) permanently discontinued RYBREVANT® due to ILD/pneumonitis.

Monitor patients for new or worsening symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). Immediately withhold RYBREVANT FASPRO™ or RYBREVANT® and LAZCLUZE® (when applicable) in patients with suspected ILD/pneumonitis and permanently discontinue if ILD/pneumonitis is confirmed.

Venous Thromboembolic (VTE) Events with Concomitant Use with LAZCLUZE®

RYBREVANT FASPRO™ and RYBREVANT® in combination with LAZCLUZE® can cause serious and fatal venous thromboembolic (VTE) events, including deep vein thrombosis and pulmonary embolism. Without prophylactic anticoagulation, the majority of these events occurred during the first four months of treatment.

RYBREVANT FASPRO™ with LAZCLUZE®

In PALOMA-3 (n=206), all Grade VTE occurred in 11% of patients and 1.5% were Grade 3. 80% (n=164) of patients received prophylactic anticoagulation at study entry, with an all Grade VTE incidence of 7%. In patients who did not receive prophylactic anticoagulation (n=42), all Grade VTE occurred in 17% of patients. In total, 0.5% of patients had VTE leading to dose reductions of RYBREVANT FASPRO™ and no patients required permanent discontinuation. The median time to onset of VTEs was 95 days (range: 17 to 390).

RYBREVANT® with LAZCLUZE®

In MARIPOSA (n=421), VTEs occurred in 36% of patients including Grade 3 in 10% and Grade 4 in 0.5% of patients. On-study VTEs occurred in 1.2% of patients (n=5) while receiving anticoagulation therapy. There were two fatal cases of VTE (0.5%), 9% of patients had VTE leading to dose interruptions of RYBREVANT®, and 7% of patients had VTE leading to dose interruptions of LAZCLUZE®; 1% of patients had VTE leading to dose reductions of RYBREVANT®, and 0.5% of patients had VTE leading to dose reductions of LAZCLUZE®; 3.1% of patients had VTE leading to permanent discontinuation of RYBREVANT®, and 1.9% of patients had VTE leading to permanent discontinuation of LAZCLUZE®. The median time to onset of VTEs was 84 days (range: 6 to 777).

Administer prophylactic anticoagulation for the first four months of treatment. The use of Vitamin K antagonists is not recommended.

Monitor for signs and symptoms of VTE events and treat as medically appropriate. Withhold RYBREVANT FASPRO™ or RYBREVANT® and LAZCLUZE® based on severity. Once anticoagulant treatment has been initiated, resume RYBREVANT FASPRO™ or RYBREVANT® and LAZCLUZE® at the same dose level at the discretion of the healthcare provider. In the event of VTE recurrence despite therapeutic anticoagulation, permanently discontinue RYBREVANT FASPRO™ or RYBREVANT®. Treatment can continue with LAZCLUZE® at the same dose level at the discretion of the healthcare provider. Refer to the LAZCLUZE® Prescribing Information for recommended LAZCLUZE® dosage modification.

Dermatologic Adverse Reactions

RYBREVANT FASPRO™ and RYBREVANT® can cause severe rash including toxic epidermal necrolysis (TEN), dermatitis acneiform, pruritus and dry skin.

RYBREVANT FASPRO™ with LAZCLUZE®

In PALOMA-3, rash occurred in 80% of patients, including Grade 3 in 17% and Grade 4 in 0.5% of patients. Rash leading to dose reduction occurred in 11% of patients, and RYBREVANT FASPRO™ was permanently discontinued due to rash in 1.5% of patients.

RYBREVANT® with LAZCLUZE®

In MARIPOSA, rash occurred in 86% of patients, including Grade 3 in 26% of patients. The median time to onset of rash was 14 days (range: 1 to 556 days). Rash leading to dose interruptions occurred in 37% of patients for RYBREVANT® and 30% for LAZCLUZE®, rash leading to dose reductions occurred in 23% of patients for RYBREVANT® and 19% for LAZCLUZE®, and rash leading to permanent discontinuation occurred in 5% of patients for RYBREVANT® and 1.7% for LAZCLUZE®.

RYBREVANT® with Carboplatin and Pemetrexed

Based on the pooled safety population, rash occurred in 82% of patients, including Grade 3 (15%) adverse reactions. Rash leading to dose reductions occurred in 14% of patients, and 2.5% permanently discontinued RYBREVANT® and 3.1% discontinued pemetrexed.

RYBREVANT® as a Single Agent

In CHRYSALIS, rash occurred in 74% of patients, including Grade 3 in 3.3% of patients. The median time to onset of rash was 14 days (range: 1 to 276 days). Rash leading to dose reduction occurred in 5% and permanent discontinuation due to rash occurred in 0.7% of patients. Toxic epidermal necrolysis occurred in one patient (0.3%).

When initiating treatment with RYBREVANT FASPRO or RYBREVANT and LAZCLUZE, prophylactic and concomitant medications are recommended to reduce the risk and severity of dermatologic adverse reactions. Instruct patients to limit sun exposure during and for 2 months after treatment. Advise patients to wear protective clothing and use broad spectrum UVA/UVB sunscreen.

If skin reactions develop, administer supportive care including topical corticosteroids and topical and/or oral antibiotics. For Grade 3 reactions, add oral steroids and consider dermatologic consultation. Promptly refer patients presenting with severe rash, atypical appearance or distribution, or lack of improvement within 2 weeks to a dermatologist. For patients receiving RYBREVANT FASPRO™ or RYBREVANT® in combination with LAZCLUZE®, withhold, reduce the dose, or permanently discontinue both drugs based on severity. For patients receiving RYBREVANT FASPRO™ or RYBREVANT® as a single agent or in combination with carboplatin and pemetrexed, withhold, dose reduce or permanently discontinue RYBREVANT FASPRO™ or RYBREVANT® based on severity.

Hepatotoxicity

LAZCLUZE® in combination with amivantamab can cause severe hepatotoxicity (including increased ALT and AST).

RYBREVANT® with LAZCLUZE®

In MARIPOSA, based on adverse reaction data, hepatotoxicity occurred in 49% of patients treated with LAZCLUZE®, including Grade 3 in 9.3% of patients and Grade 4 in 0.5%. LAZCLUZE® was interrupted for an adverse reaction of hepatotoxicity in 8% of patients, the dose was reduced in 1.4% and permanently discontinued in 0.2%.

Perform liver function tests (including ALT, AST, and total bilirubin) before initiation of LAZCLUZE® and during treatment, as clinically indicated. Withhold, reduce the dose, or permanently discontinue LAZCLUZE® and amivantamab based on severity.

Ocular Toxicity

RYBREVANT FASPRO™ and RYBREVANT® can cause ocular toxicity including keratitis, blepharitis, dry eye symptoms, conjunctival redness, blurred vision, visual impairment, ocular itching, eye pruritus and uveitis.

RYBREVANT FASPRO™ with LAZCLUZE®

In PALOMA-3, all Grade ocular toxicity occurred in 13% of patients, including 0.5% Grade 3.

RYBREVANT® with LAZCLUZE®

In MARIPOSA, ocular toxicity occurred in 16%, including Grade 3 or 4 ocular toxicity in 0.7% of patients.

RYBREVANT® with Carboplatin and Pemetrexed

Based on the pooled safety population, ocular toxicity occurred in 16% of patients. All events were Grade 1 or 2.

RYBREVANT® as a Single Agent

In CHRYSALIS, keratitis occurred in 0.7% and uveitis occurred in 0.3% of patients. All events were Grade 1-2.

Promptly refer patients presenting with new or worsening eye symptoms to an ophthalmologist. Withhold, dose reduce or permanently discontinue RYBREVANT FASPRO™ or RYBREVANT® and continue LAZCLUZE® based on severity.

Embryo-Fetal Toxicity

Based on animal models, RYBREVANT FASPRO™, RYBREVANT® and LAZCLUZE® can cause fetal harm when administered to a pregnant woman. Verify pregnancy status of females of reproductive potential prior to initiating RYBREVANT FASPRO™ and RYBREVANT®. Advise pregnant women and females of reproductive potential of the potential risk to the fetus. Advise patients of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of RYBREVANT FASPRO™ or RYBREVANT®, and for 3 weeks after the last dose of LAZCLUZE®.

ADVERSE REACTIONS

RYBREVANT FASPRO™ with LAZCLUZE®

In PALOMA-3 (n=206), the most common adverse reactions (≥20%) were rash (80%), nail toxicity (58%), musculoskeletal pain (50%), fatigue (37%), stomatitis (36%), edema (34%), nausea (30%), diarrhea (22%), vomiting (22%), constipation (22%), decreased appetite (22%), and headache (21%). The most common Grade 3 or 4 laboratory abnormalities (≥2%) were decreased lymphocyte count (6%), decreased sodium (5%), decreased potassium (5%), decreased albumin (4.9%), increased alanine aminotransferase (3.4%), decreased platelet count (2.4%), increased aspartate aminotransferase (2%), increased gamma-glutamyl transferase (2%), and decreased hemoglobin (2%).

Serious adverse reactions occurred in 33% of patients, with those occurring in ≥2% of patients including ILD/pneumonitis (6%); and pneumonia, VTE and fatigue (2.4% each). Death due to adverse reactions occurred in 5% of patients treated with RYBREVANT FASPRO™, including ILD/pneumonitis (1.9%), pneumonia (1.5%), and respiratory failure and sudden death (1% each).

RYBREVANT® with LAZCLUZE®

In MARIPOSA (n=421), the most common adverse reactions (ARs) (≥20%) were rash (86%), nail toxicity (71%), infusion-related reactions (IRRs) (RYBREVANT®) (63%), musculoskeletal pain (47%), stomatitis (43%), edema (43%), VTE (36%), paresthesia (35%), fatigue (32%), diarrhea (31%), constipation (29%), COVID-19 (26%), hemorrhage (25%), dry skin (25%), decreased appetite (24%), pruritus (24%), and nausea (21%). The most common Grade 3 or 4 laboratory abnormalities (≥2%) were decreased albumin (8%), decreased sodium (7%), increased ALT (7%), decreased potassium (5%), decreased hemoglobin (3.8%), increased AST (3.8%), increased GGT (2.6%), and increased magnesium (2.6%).

Serious ARs occurred in 49% of patients, with those occurring in ≥2% of patients including VTE (11%), pneumonia (4%), ILD/pneumonitis and rash (2.9% each), COVID-19 (2.4%), and pleural effusion and IRRs (RYBREVANT®) (2.1% each). Fatal ARs occurred in 7% of patients due to death not otherwise specified (1.2%); sepsis and respiratory failure (1% each); pneumonia, myocardial infarction, and sudden death (0.7% each); cerebral infarction, pulmonary embolism (PE), and COVID-19 infection (0.5% each); and ILD/pneumonitis, acute respiratory distress syndrome (ARDS), and cardiopulmonary arrest (0.2% each).

RYBREVANT® with Carboplatin and Pemetrexed

In MARIPOSA-2 (n=130), the most common ARs (≥20%) were rash (72%), IRRs (59%), fatigue (51%), nail toxicity (45%), nausea (45%), constipation (39%), edema (36%), stomatitis (35%), decreased appetite (31%), musculoskeletal pain (30%), vomiting (25%), and COVID-19 (21%). The most common Grade 3 to 4 laboratory abnormalities (≥2%) were decreased neutrophils (49%), decreased white blood cells (42%), decreased lymphocytes (28%), decreased platelets (17%), decreased hemoglobin (12%), decreased potassium (11%), decreased sodium (11%), increased alanine aminotransferase (3.9%), decreased albumin (3.8%), and increased gamma-glutamyl transferase (3.1%).

In MARIPOSA-2, serious ARs occurred in 32% of patients, with those occurring in >2% of patients including dyspnea (3.1%), thrombocytopenia (3.1%), sepsis (2.3%), and PE (2.3%). Fatal ARs occurred in 2.3% of patients; these included respiratory failure, sepsis, and ventricular fibrillation (0.8% each).

In PAPILLON (n=151), the most common ARs (≥20%) were rash (90%), nail toxicity (62%), stomatitis (43%), IRRs (42%), fatigue (42%), edema (40%), constipation (40%), decreased appetite (36%), nausea (36%), COVID-19 (24%), diarrhea (21%), and vomiting (21%). The most common Grade 3 to 4 laboratory abnormalities (≥2%) were decreased albumin (7%), increased alanine aminotransferase (4%), increased gamma-glutamyl transferase (4%), decreased sodium (7%), decreased potassium (11%), decreased magnesium (2%), and decreases in white blood cells (17%), hemoglobin (11%), neutrophils (36%), platelets (10%), and lymphocytes (11%).

In PAPILLON, serious ARs occurred in 37% of patients, with those occurring in ≥2% of patients including rash, pneumonia, ILD, PE, vomiting, and COVID-19. Fatal adverse reactions occurred in 7 patients (4.6%) due to pneumonia, cerebrovascular accident, cardio-respiratory arrest, COVID-19, sepsis, and death not otherwise specified.

RYBREVANT® as a Single Agent

In CHRYSALIS (n=129), the most common ARs (≥20%) were rash (84%), IRR (64%), paronychia (50%), musculoskeletal pain (47%), dyspnea (37%), nausea (36%), fatigue (33%), edema (27%), stomatitis (26%), cough (25%), constipation (23%), and vomiting (22%). The most common Grade 3 to 4 laboratory abnormalities (≥2%) were decreased lymphocytes (8%), decreased albumin (8%), decreased phosphate (8%), decreased potassium (6%), increased alkaline phosphatase (4.8%), increased glucose (4%), increased gamma-glutamyl transferase (4%), and decreased sodium (4%).

Serious ARs occurred in 30% of patients, with those occurring in ≥2% of patients including PE, pneumonitis/ILD, dyspnea, musculoskeletal pain, pneumonia, and muscular weakness. Fatal adverse reactions occurred in 2 patients (1.5%) due to pneumonia and 1 patient (0.8%) due to sudden death.

LAZCLUZE® DRUG INTERACTIONS

Avoid concomitant use of LAZCLUZE® with strong and moderate CYP3A4 inducers. Consider an alternate concomitant medication with no potential to induce CYP3A4.

Monitor for adverse reactions associated with a CYP3A4 or BCRP substrate where minimal concentration changes may lead to serious adverse reactions, as recommended in the approved product labeling for the CYP3A4 or BCRP substrate.

Please see full Prescribing Information for RYBREVANT FASPRO™, RYBREVANT® and LAZCLUZE®.

cp-491009v2

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com. Follow us at @JNJInnovMed.

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of RYBREVANT®-based regimens. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

*Barbara Burtness, M.D. has served as a consultant to Johnson & Johnson; she has not been paid for any media work.

† RECIST (version 1.1) refers to Response Evaluation Criteria in Solid Tumors, which is a standard way to measure how well solid tumors respond to treatment and is based on whether tumors shrink, stay the same or get bigger.

‡ Once monthly after weekly injections from weeks 1-4.

§ The NCCN content does not constitute medical advice and should not be used in place of seeking professional medical advice, diagnosis or treatment by licensed practitioners. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

|| See the NCCN Guidelines for detailed recommendations, including other treatment options.

¶ The NCCN Guidelines for NSCLC provide recommendations for certain individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays or commercial laboratories.

1 Burtness B, et al. Amivantamab in recurrent/metastatic head & neck squamous cell cancer after disease progression on immune checkpoint inhibitor and chemotherapy. Pivotal results from the phase 1b/2 OrigAMI-4 study. Presented at: The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting; May 31, 2026; Chicago, Illinois.
2 Burtness B, et al. Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 study. Epub May 31, 2026. doi:10.1200/JCO-26-01042.
3 Zebralla V, Wichmann G, Pirlich M, et al. Dysphagia, voice problems, and pain in head and neck cancer patients. Eur Arch Otorhinolaryngol. 2021;278(10):3985-3994. doi:10.1007/s00405-020-06584-6
4 Nissi L, et al. Recurrence of head and neck squamous cell carcinoma in relation to high-risk treatment volume. Clin Transl Radiat Oncol. 2021;27:139-146. doi:10.1016/j.ctro.2021.01.013
5 Dunn LA, Ho AL, Pfister DG. Head and neck cancer: a review. JAMA. 2026;335(6):531-541. doi:10.1001/jama.2025.21733
6 Soulieres D, et al. LBA48 BURAN: A phase III study of buparlisib (BUP) plus paclitaxel (PAC) in patients with PD-1(PD-L1)-pretreated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Ann Oncol. 2025;36:S1707.
7 Fayette J, et al. INTERLINK-1: A Phase III, randomized, placebo-controlled study of monalizumab plus cetuximab in recurrent/metastatic head and neck squamous cell carcinoma. Clin Cancer Res. 2025;31(13):2617-2627. doi:10.1158/1078-0432.CCR-25-0073
8 Große-Thie C, Maletzki C, Junghanss C, Schmidt K. Long-term survivor of metastatic squamous-cell head and neck carcinoma with occult primary after cetuximab-based chemotherapy: A case report. World J Clin Cases. 2021;9(24):7092-7098. doi:10.12998/wjcc.v9.i24.7092
9 Harrington KJ, Rosenberg AJ, Yang MH, et al. Subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell cancer after disease progression on checkpoint inhibitor and chemotherapy: Preliminary results from the phase 1b/2 OrigAMI-4 study. Oral Oncol. 2025;171:107791. doi:10.1016/j.oraloncology.2025.107791
10 Haddad R, et al. OrigAMI-5: A randomized, phase 3 study of amivantamab plus pembrolizumab and carboplatin vs standard of care pembrolizumab plus platinum and 5-fluorouracil as first-line treatment in recurrent/metastatic head and neck cancer. Presented at: The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting; May 30, 2026; Chicago, Illinois.
11 RYBREVANT FASPRO™ Prescribing Information. Horsham, PA: Janssen Biotech, Inc.
12 ClinicalTrials.gov. A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/ Metastatic Head and Neck Cancer (OrigAMI-4). https://clinicaltrials.gov/study/NCT06385080?term=OrigAMI-4&limit=10&rank=1. Accessed May 2026.
13 Barsouk A, Aluru JS, Rawla P, Saginala K, Barsouk A. Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma. Med Sci (Basel). 2023;11(2):42. Published 2023 Jun 13. doi:10.3390/medsci11020042
14 Ghiani L, Chiocca S. High Risk-Human Papillomavirus in HNSCC: Present and Future Challenges for Epigenetic Therapies. International Journal of Molecular Sciences. 2022;23(7):3483. https://doi.org/10.3390/ijms23073483
15 Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. New England Journal of Medicine. 2016;375(19):1856-1867. doi:10.1056/NEJMoa1602252
16 Wise-Draper TM, Bahig H, Tonneau M, Karivedu V, Burtness B. Current Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges. Am Soc Clin Oncol Educ Book. 2022;42:1-14. doi:10.1200/EDBK_350442
17 Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.3.2026 © National Comprehensive Cancer Network, Inc. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org. Accessed May 2026.
18 RYBREVANT® Prescribing Information. Horsham, PA: Janssen Biotech, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-pivotal-data-show-strong-and-durable-responses-in-advanced-head-and-neck-cancer-where-options-remain-limited-302786430.html

SOURCE Johnson & Johnson

GUADALAJARA, Mexico, June 05, 2026 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces preliminary terminal passenger traffic figures for May 2026, compared with May 2025.

During May 2026, the 12 Mexican airports operated by GAP recorded a 2.8% decrease in total passenger traffic compared to May 2025. Guadalajara airport reported an increase of 7.1%, while Puerto Vallarta, Tijuana and Los Cabos reported a decrease of 14.4%, 9.8%, and 6.0%, respectively, compared to May 2025. With respect to GAP’s airports in Jamaica, Montego Bay recorded a decrease of 19.1%, while Montego Bay recorded a decrease of 5.2%.

Domestic Terminal Passengers (in thousands):       AirportMay-25May-26% ChangeJan - May 25Jan - May 26% ChangeGuadalajara1,023.41,085.96.1%5,112.05,187.71.5%Tijuana*730.5664.5(9.0%)3,536.63,304.7(6.6%)Los Cabos245.0247.00.8%1,168.51,116.2(4.5%)Puerto Vallarta278.2266.7(4.1%)1,210.21,166.5(3.6%)Montego Bay0.00.0N/A0.00.0N/AGuanajuato194.1181.3(6.6%)903.7871.3(3.6%)Hermosillo184.5179.1(2.9%)877.6825.7(5.9%)Kingston0.00.1140.0%0.10.8489.7%Morelia59.455.6(6.3%)305.6306.90.4%La Paz107.0122.014.0%499.4559.111.9%Mexicali103.686.9(16.1%)501.8437.1(12.9%)Aguascalientes60.753.6(11.6%)265.8247.7(6.8%)Los Mochis58.161.55.8%289.6285.5(1.4%)Manzanillo10.310.0(2.4%)55.852.8(5.3%)Total3,054.63,014.2(1.3%)14,726.714,361.9(2.5%) International Terminal Passengers (in thousands):       AirportMay-25May-26% ChangeJan - May 25Jan - May 26% ChangeGuadalajara457.5499.99.3%2,417.42,459.21.7%Tijuana*336.6297.9(11.5%)1,702.51,508.3(11.4%)Los Cabos367.3328.8(10.5%)2,193.22,101.6(4.2%)Puerto Vallarta236.1173.5(26.5%)2,084.31,740.0(16.5%)Montego Bay395.4320.1(19.1%)2,164.81,573.0(27.3%)Guanajuato80.371.9(10.4%)427.7402.0(6.0%)Hermosillo6.77.714.7%33.736.68.5%Kingston146.3138.7(5.2%)729.3699.2(4.1%)Morelia49.762.625.9%279.9343.322.7%La Paz3.14.751.9%14.821.948.2%Mexicali0.50.729.5%2.93.05.7%Aguascalientes28.729.00.9%129.8135.74.6%Los Mochis0.70.76.4%3.23.31.9%Manzanillo5.14.7(6.3%)58.749.3(16.1%)Total2,113.91,940.9(8.2%)12,242.211,076.4(9.5%) Total Terminal Passengers (in thousands):         AirportMay-25May-26% ChangeJan - May 25Jan - May 26% ChangeGuadalajara1,480.81,585.87.1%7,529.47,646.91.6%Tijuana*1,067.1962.4(9.8%)5,239.24,813.0(8.1%)Los Cabos612.3575.8(6.0%)3,361.73,217.8(4.3%)Puerto Vallarta514.3440.2(14.4%)3,294.52,906.5(11.8%)Montego Bay395.4320.1(19.1%)2,164.81,573.0(27.3%)Guanajuato274.4253.3(7.7%)1,331.41,273.3(4.4%)Hermosillo191.2186.8(2.3%)911.3862.3(5.4%)Kingston146.4138.8(5.2%)729.5700.0(4.0%)Morelia109.0118.28.4%585.5650.211.0%La Paz110.1126.815.1%514.2581.013.0%Mexicali104.187.6(15.9%)504.6440.2(12.8%)Aguascalientes89.382.6(7.6%)395.6383.4(3.1%)Los Mochis58.762.15.9%292.8288.8(1.4%)Manzanillo15.414.8(3.7%)114.5102.1(10.9%)Total5,168.54,955.2(4.1%)26,968.825,438.4(5.7%) *Passengers in Tijuana who use CBX in both directions are classified as international.

CBX users (in thousands):           AirportMay-25May-26% ChangeJan - May 25Jan - May 26% ChangeTijuana329.8293.5(11.0%)1,673.01,489.2(11.0%)        Highlights for the month:

Seats and load factors
The seats available during May 2026 decreased by 7.5%, compared to May 2025. The load factors for the month went from 81.1% in May 2025 to 84.1% in May 2026. Company Description

Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (GAP) operates 12 airports throughout Mexico’s Pacific region, including the major cities of Guadalajara and Tijuana, the four tourist destinations of Puerto Vallarta, Los Cabos, La Paz and Manzanillo, and six other mid-sized cities: Hermosillo, Guanajuato, Morelia, Aguascalientes, Mexicali, and Los Mochis. In February 2006, GAP’s shares were listed on the New York Stock Exchange under the ticker symbol “PAC” and on the Mexican Stock Exchange under the ticker symbol “GAP”. In April 2015, GAP acquired 100% of Desarrollo de Concessioner Aeroportuarias, S.L., which owns a majority stake in MBJ Airports Limited, a company operating Sangster International Airport in Montego Bay, Jamaica. In October 2018, GAP entered into a concession agreement for the Norman Manley International Airport operation in Kingston, Jamaica, and took control of the operation in October 2019.

This press release may contain forward-looking statements. These statements are statements that are not historical facts and are based on management’s current view and estimates of future economic circumstances, industry conditions, company performance, and financial results. The words “anticipates”, “believes”, “estimates”, “expects”, “plans” and similar expressions, as they relate to the company, are intended to identify forward-looking statements. Statements regarding the declaration or payment of dividends, the implementation of principal operating and financing strategies and capital expenditure plans, the direction of future operations, and the factors or trends affecting financial condition, liquidity, or results of operations are examples of forward-looking statements. Such statements reflect the current views of management and are subject to a number of risks and uncertainties. There is no guarantee that the expected events, trends, or results will occur. The statements are based on many assumptions and factors, including general economic and market conditions, industry conditions, and operating factors. Any changes in such assumptions or factors could cause actual results to differ materially from current expectations.    In accordance with Section 806 of the Sarbanes-Oxley Act of 2002 and Article 42 of the “Ley del Mercado de Valores”, GAP has implemented a “whistleblower” program, which allows complainants to anonymously and confidentially report suspected activities that involve criminal conduct or violations. The telephone number in Mexico, facilitated by a third party responsible for collecting these complaints, is 800 04 ETICA (38422) or WhatsApp +52 55 6538 5504. The website is www.lineadedenunciagap.com or by email at [email protected]. GAP’s Audit Committee will be notified of all complaints for immediate investigation.

Alejandra Soto, Investor Relations and Social Responsibility OfficerGisela Murillo, Investor Relations

[email protected]@aeropuertosgap.com.mx
+52 33 3880 1100 ext. 20294

  

LOS ANGELES--(BUSINESS WIRE)---- $XPOF--XPOF Investors Have Opportunity to Join Xponential Fitness, Inc. Fraud Investigation with the Schall Law Firm.